CN107778446A - Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break - Google Patents
Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break Download PDFInfo
- Publication number
- CN107778446A CN107778446A CN201710971002.9A CN201710971002A CN107778446A CN 107778446 A CN107778446 A CN 107778446A CN 201710971002 A CN201710971002 A CN 201710971002A CN 107778446 A CN107778446 A CN 107778446A
- Authority
- CN
- China
- Prior art keywords
- polyurethane
- degradable
- elongation
- compound
- diisocyanate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004814 polyurethane Substances 0.000 title claims abstract description 104
- 229920002635 polyurethane Polymers 0.000 title claims abstract description 101
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 40
- 230000015556 catabolic process Effects 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000004970 Chain extender Substances 0.000 claims abstract description 28
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 224
- 238000006243 chemical reaction Methods 0.000 claims description 120
- 239000000463 material Substances 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 55
- -1 sulphur Sugar alcohol Chemical class 0.000 claims description 54
- 229920000642 polymer Polymers 0.000 claims description 48
- 239000003960 organic solvent Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 36
- 239000003054 catalyst Substances 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 35
- 239000012467 final product Substances 0.000 claims description 34
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 23
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 23
- 229910000861 Mg alloy Inorganic materials 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 21
- 238000000576 coating method Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 19
- 239000007769 metal material Substances 0.000 claims description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 18
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical class OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 18
- 239000002861 polymer material Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 16
- 210000003708 urethra Anatomy 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 13
- 239000004472 Lysine Substances 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 13
- 238000007605 air drying Methods 0.000 claims description 13
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 239000000956 alloy Substances 0.000 claims description 12
- 125000005442 diisocyanate group Chemical group 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 10
- 238000003618 dip coating Methods 0.000 claims description 10
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 claims description 9
- 229910045601 alloy Inorganic materials 0.000 claims description 9
- 239000002872 contrast media Substances 0.000 claims description 9
- 238000002513 implantation Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 150000001621 bismuth Chemical class 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 239000012948 isocyanate Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- 210000000626 ureter Anatomy 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 125000004494 ethyl ester group Chemical group 0.000 claims description 6
- 229910000838 Al alloy Inorganic materials 0.000 claims description 5
- 229910000882 Ca alloy Inorganic materials 0.000 claims description 5
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 238000004898 kneading Methods 0.000 claims description 5
- 238000002161 passivation Methods 0.000 claims description 5
- 229910019089 Mg-Fe Inorganic materials 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 210000003445 biliary tract Anatomy 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- 210000002429 large intestine Anatomy 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 229910052726 zirconium Inorganic materials 0.000 claims description 3
- FDYWJVHETVDSRA-UHFFFAOYSA-N 1,1-diisocyanatobutane Chemical compound CCCC(N=C=O)N=C=O FDYWJVHETVDSRA-UHFFFAOYSA-N 0.000 claims description 2
- 229940008841 1,6-hexamethylene diisocyanate Drugs 0.000 claims description 2
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical class OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 229910052684 Cerium Inorganic materials 0.000 claims description 2
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims description 2
- 235000005513 chalcones Nutrition 0.000 claims description 2
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical class OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- SXCBDZAEHILGLM-UHFFFAOYSA-N heptane-1,7-diol Chemical class OCCCCCCCO SXCBDZAEHILGLM-UHFFFAOYSA-N 0.000 claims description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical class OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims description 2
- 229960002725 isoflurane Drugs 0.000 claims description 2
- 229910052746 lanthanum Inorganic materials 0.000 claims description 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 2
- AYLRODJJLADBOB-QMMMGPOBSA-N methyl (2s)-2,6-diisocyanatohexanoate Chemical compound COC(=O)[C@@H](N=C=O)CCCCN=C=O AYLRODJJLADBOB-QMMMGPOBSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 claims description 2
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims 3
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 claims 1
- OTXKQKKLEDBPAD-LURJTMIESA-N ethyl (2s)-2,5-diaminopentanoate Chemical compound CCOC(=O)[C@@H](N)CCCN OTXKQKKLEDBPAD-LURJTMIESA-N 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- SXZCBVCQHOJXDR-ILKKLZGPSA-N hydron;methyl (2s)-2,6-diaminohexanoate;dichloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CCCCN SXZCBVCQHOJXDR-ILKKLZGPSA-N 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 239000007943 implant Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000001172 regenerating effect Effects 0.000 abstract description 4
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 239000003921 oil Substances 0.000 description 62
- 235000019198 oils Nutrition 0.000 description 62
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 54
- 239000010408 film Substances 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 18
- 235000018977 lysine Nutrition 0.000 description 18
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 16
- 230000032050 esterification Effects 0.000 description 16
- 238000005886 esterification reaction Methods 0.000 description 16
- 229920000117 poly(dioxanone) Polymers 0.000 description 15
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229960003646 lysine Drugs 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229920000747 poly(lactic acid) Polymers 0.000 description 11
- 239000004626 polylactic acid Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 239000011572 manganese Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 8
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 7
- 229920000954 Polyglycolide Polymers 0.000 description 7
- 229910052748 manganese Inorganic materials 0.000 description 7
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- 229910052797 bismuth Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- SORGMJIXNUWMMR-UHFFFAOYSA-N lanthanum(3+);propan-2-olate Chemical compound [La+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SORGMJIXNUWMMR-UHFFFAOYSA-N 0.000 description 5
- 235000008729 phenylalanine Nutrition 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- NXQMCAOPTPLPRL-UHFFFAOYSA-N 2-(2-benzoyloxyethoxy)ethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCOCCOC(=O)C1=CC=CC=C1 NXQMCAOPTPLPRL-UHFFFAOYSA-N 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000009477 glass transition Effects 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- 238000010146 3D printing Methods 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000007625 Hirudins Human genes 0.000 description 3
- 108010007267 Hirudins Proteins 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- AYOHIQLKSOJJQH-UHFFFAOYSA-N dibutyltin Chemical compound CCCC[Sn]CCCC AYOHIQLKSOJJQH-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229940060037 fluorine Drugs 0.000 description 3
- 229940117955 isoamyl acetate Drugs 0.000 description 3
- 235000005772 leucine Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JBBURJFZIMRPCZ-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;hydron;dichloride Chemical compound Cl.Cl.NCCCC[C@H](N)C(O)=O JBBURJFZIMRPCZ-XRIGFGBMSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MTVOSXTZNVKGIF-UHFFFAOYSA-N 2,3-dimethoxy-12-methyl-13h-[1,3]benzodioxolo[5,6-c]phenanthridine Chemical compound C1=C2C(N(C)CC=3C=C(C(=CC=33)OC)OC)=C3C=CC2=CC2=C1OCO2 MTVOSXTZNVKGIF-UHFFFAOYSA-N 0.000 description 2
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 description 2
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical compound C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 229910014460 Ca-Fe Inorganic materials 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910000881 Cu alloy Inorganic materials 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NESVMZOPWPCFAU-UHFFFAOYSA-N Ergoclavinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C)C2)=C3C2=CNC3=C1 NESVMZOPWPCFAU-UHFFFAOYSA-N 0.000 description 2
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 2
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- 244000097577 Rhus javanica Species 0.000 description 2
- 235000010889 Rhus javanica Nutrition 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- NSPSPMKCKIPQBH-UHFFFAOYSA-K bismuth;7,7-dimethyloctanoate Chemical compound [Bi+3].CC(C)(C)CCCCCC([O-])=O.CC(C)(C)CCCCCC([O-])=O.CC(C)(C)CCCCCC([O-])=O NSPSPMKCKIPQBH-UHFFFAOYSA-K 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 150000004985 diamines Chemical group 0.000 description 2
- HGQSXVKHVMGQRG-UHFFFAOYSA-N dioctyltin Chemical compound CCCCCCCC[Sn]CCCCCCCC HGQSXVKHVMGQRG-UHFFFAOYSA-N 0.000 description 2
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 229960001405 ergometrine Drugs 0.000 description 2
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 2
- 229960004943 ergotamine Drugs 0.000 description 2
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
- FYIBGDKNYYMMAG-UHFFFAOYSA-N ethane-1,2-diol;terephthalic acid Chemical compound OCCO.OC(=O)C1=CC=C(C(O)=O)C=C1 FYIBGDKNYYMMAG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011806 microball Substances 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- ALTGURJQVWBILJ-UHFFFAOYSA-N n-(dimethylamino)formamide Chemical compound CN(C)NC=O ALTGURJQVWBILJ-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 150000002994 phenylalanines Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 239000005056 polyisocyanate Substances 0.000 description 2
- 229920001228 polyisocyanate Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 2
- 229960004558 terguride Drugs 0.000 description 2
- 239000012974 tin catalyst Substances 0.000 description 2
- JNXDCMUUZNIWPQ-UHFFFAOYSA-N trioctyl benzene-1,2,4-tricarboxylate Chemical compound CCCCCCCCOC(=O)C1=CC=C(C(=O)OCCCCCCCC)C(C(=O)OCCCCCCCC)=C1 JNXDCMUUZNIWPQ-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- URWAJWIAIPFPJE-VHLNBGGKSA-N (2r,3r,4r,5r)-2-[(1s,2r,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-VHLNBGGKSA-N 0.000 description 1
- NTUPOKHATNSWCY-PMPSAXMXSA-N (2s)-2-[[(2s)-1-[(2r)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-PMPSAXMXSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- KVTCHSWVSFQOTP-YFPNSAJKSA-N (2z)-2-[(2r,3s,4s)-4-hydroxy-2-(3-hydroxypropyl)-3-[(3e,5r,7e)-5-hydroxy-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dimethylcyclohexylidene]propanal Chemical compound CC(C)=CCC\C(C)=C\C[C@@H](O)C(\C)=C\CC[C@@]1(C)[C@H](CCCO)\C(=C(\C)C=O)CC[C@]1(C)O KVTCHSWVSFQOTP-YFPNSAJKSA-N 0.000 description 1
- KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- CTNPHHZPAJYPFO-PDXBGNJTSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5r,6r)-5-[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C=O)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@@H]2[C@H]([C@H](O)[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](CO)O2)O)OC)=CC(=O)OC1 CTNPHHZPAJYPFO-PDXBGNJTSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- GENAHGKEFJLNJB-IINYFYTJSA-N (6ar,9s)-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C2=C[C@@H](CN([C@@H]2C2)C)C(N)=O)=C3C2=CNC3=C1 GENAHGKEFJLNJB-IINYFYTJSA-N 0.000 description 1
- ZAGRKAFMISFKIO-IINYFYTJSA-N (6ar,9s)-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxylic acid Chemical compound C1=CC(C2=C[C@@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-IINYFYTJSA-N 0.000 description 1
- SORYERHBQFTRIK-XMLQBHOOSA-N (6e,10z,14z)-6,14-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,12,13,15a-octahydrocyclotetradeca[b]furan-10-carboxylic acid Chemical compound C1CC(/C)=C/CC\C(C(O)=O)=C\CC\C(C)=C/C2OC(=O)C(=C)C21 SORYERHBQFTRIK-XMLQBHOOSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- PAQLRHWWLDIBHD-UHFFFAOYSA-N 16-hydroxyiridal Natural products CC(CC=C(C)C)C=CCC(O)C(=CCCC1(C)C(CCCO)C(=C(C)/C=O)CCC1(C)O)C PAQLRHWWLDIBHD-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- SBHNNNRQZGYOAU-YVEFUNNKSA-N 3-[(6ar,9s)-5-bromo-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=C(Br)NC3=C1 SBHNNNRQZGYOAU-YVEFUNNKSA-N 0.000 description 1
- FCRJELOYDVBTGW-ILZDJORESA-N 3-[(6ar,9s,10ar)-7-propyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea Chemical compound C1=CC([C@H]2C[C@@H](CN([C@@H]2C2)CCC)NC(=O)N(CC)CC)=C3C2=CNC3=C1 FCRJELOYDVBTGW-ILZDJORESA-N 0.000 description 1
- YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- TUGAUFMQYWZJAB-FPLPWBNLSA-N 5-[(8Z)-pentadec-8-enyl]resorcinol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC(O)=CC(O)=C1 TUGAUFMQYWZJAB-FPLPWBNLSA-N 0.000 description 1
- YKVIWISPFDZYOW-UHFFFAOYSA-N 6-Decanolide Chemical compound CCCCC1CCCCC(=O)O1 YKVIWISPFDZYOW-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- YDOTUXAWKBPQJW-JJANYQHSSA-N 919k69s85n Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-JJANYQHSSA-N 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- XJOOMMHNYOJWCZ-UHFFFAOYSA-N Agroclavine Natural products C1=CC(C2C=C(C)CN(C2C2)C)=C3C2=CNC3=C1 XJOOMMHNYOJWCZ-UHFFFAOYSA-N 0.000 description 1
- KVVMQRLBODZZRT-UHFFFAOYSA-N Amethystoidin A Natural products C1C(=O)C2C3(C)CCCC(C)(CO)C3CC(O)C22C(=O)C(=C)C1C2O KVVMQRLBODZZRT-UHFFFAOYSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- SORYERHBQFTRIK-UHFFFAOYSA-N Anisomelic Acid Natural products C1CC(C)=CCCC(C(O)=O)=CCCC(C)=CC2OC(=O)C(=C)C21 SORYERHBQFTRIK-UHFFFAOYSA-N 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- SRLTUZDQBFYLQI-FPLPWBNLSA-N Bilobol Natural products Oc1c(CCCCCCC/C=C\CCCCCC)ccc(O)c1 SRLTUZDQBFYLQI-FPLPWBNLSA-N 0.000 description 1
- 101001051969 Bos taurus Fibroblast growth factor 2 Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- MLBWYQNJPOKROR-IMVWOWLCSA-N C(C)NCC.OC(=O)[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34 Chemical compound C(C)NCC.OC(=O)[C@@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34 MLBWYQNJPOKROR-IMVWOWLCSA-N 0.000 description 1
- RNVDZQQBRIIJKA-UHFFFAOYSA-N CC1=NC=CS1.C1NCOC1 Chemical compound CC1=NC=CS1.C1NCOC1 RNVDZQQBRIIJKA-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- PESZCXUNMKAYME-UHFFFAOYSA-N Citroflex A-4 Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)C(C(C)=O)C(=O)OCCCC PESZCXUNMKAYME-UHFFFAOYSA-N 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- XQCGNURMLWFQJR-ZNDDOCHDSA-N Cymarin Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 XQCGNURMLWFQJR-ZNDDOCHDSA-N 0.000 description 1
- XQCGNURMLWFQJR-UESCRGIISA-N Cymarin Natural products O=C[C@@]12[C@@](O)(C[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CC[C@H]21 XQCGNURMLWFQJR-UESCRGIISA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- UJYGDMFEEDNVBF-UHFFFAOYSA-N Ergocorninine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 description 1
- BGHDUTQZGWOQIA-VQSKNWBGSA-N Ergovaline Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C)C2)=C3C2=CNC3=C1 BGHDUTQZGWOQIA-VQSKNWBGSA-N 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 229910001021 Ferroalloy Inorganic materials 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229940123256 Fibroblast growth factor antagonist Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 241000414067 Inonotus obliquus Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- 241000554432 Isodon amethystoides Species 0.000 description 1
- FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- MEPSBMMZQBMKHM-UHFFFAOYSA-N Lomatiol Natural products CC(=C/CC1=C(O)C(=O)c2ccccc2C1=O)CO MEPSBMMZQBMKHM-UHFFFAOYSA-N 0.000 description 1
- BIXJFIJYBLJTMK-UHFFFAOYSA-N Lysergol Natural products C1=CC(C2=CC(CO)CN(C2C2)C)=C3C2=CNC3=C1 BIXJFIJYBLJTMK-UHFFFAOYSA-N 0.000 description 1
- GENAHGKEFJLNJB-UHFFFAOYSA-N Lysergsaeure-amid Natural products C1=CC(C2=CC(CN(C2C2)C)C(N)=O)=C3C2=CNC3=C1 GENAHGKEFJLNJB-UHFFFAOYSA-N 0.000 description 1
- 241000218211 Maclura Species 0.000 description 1
- 240000008152 Maytenus boaria Species 0.000 description 1
- 235000017653 Maytenus boaria Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- NOFOWWRHEPHDCY-DAUURJMHSA-N Methylergonovine Maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 NOFOWWRHEPHDCY-DAUURJMHSA-N 0.000 description 1
- 229910000914 Mn alloy Inorganic materials 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034122 Patella fracture Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- CIEYTVIYYGTCCI-UHFFFAOYSA-N SJ000286565 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- JWBVQJZXSQDXKU-DOAWMXAISA-N Sculponeatin C Chemical compound C([C@@H]1C[C@]2(C(C1=C)=O)C(=O)OC1)[C@@H](O)[C@H]2[C@@]1([C@@H]12)[C@H]3O[C@H]2OC[C@]1(C)CC3 JWBVQJZXSQDXKU-DOAWMXAISA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 1
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 1
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 1
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 1
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 1
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 229940127538 Vascular Endothelial Growth Factor Receptor Inhibitors Drugs 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- NEDJKVIUOSOCNB-AWPSVMBFSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclo Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21.O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 NEDJKVIUOSOCNB-AWPSVMBFSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- UPKBEIIDYOMDQW-UKRRQHHQSA-N agroclavine Chemical compound C1=CC=C2[C@H]3C=C(C)CN(C)[C@@H]3CC3=CN=C1[C]32 UPKBEIIDYOMDQW-UKRRQHHQSA-N 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- YDOTUXAWKBPQJW-UHFFFAOYSA-N alpha-Ergocryptinine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-UHFFFAOYSA-N 0.000 description 1
- YDOTUXAWKBPQJW-NSLWYYNWSA-N alpha-ergocryptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-NSLWYYNWSA-N 0.000 description 1
- 229950001817 alpha-ergocryptine Drugs 0.000 description 1
- QNSMDRVETBBHCI-GYHYLIPUSA-N amethystoidin a Chemical compound C1C(=O)[C@H]2[C@]3(CO)CCCC(C)(C)[C@H]3C[C@@H](O)C22C(=O)C(=C)C1[C@@H]2O QNSMDRVETBBHCI-GYHYLIPUSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950006651 bromerguride Drugs 0.000 description 1
- 229940074995 bromine Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- GNEVIACKFGQMHB-UHFFFAOYSA-N carbon suboxide Chemical compound O=C=C=C=O GNEVIACKFGQMHB-UHFFFAOYSA-N 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- CMKFQVZJOWHHDV-DYHNYNMBSA-N catharanthine Chemical compound C([C@@H]1C=C([C@@H]2[C@@]3(C1)C(=O)OC)CC)N2CCC1=C3NC2=CC=CC=C12 CMKFQVZJOWHHDV-DYHNYNMBSA-N 0.000 description 1
- GKWYINOZGDHWRA-UHFFFAOYSA-N catharanthine Natural products C1C(CC)(O)CC(CC2C(=O)OC)CN1CCC1=C2NC2=CC=CC=C12 GKWYINOZGDHWRA-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- DJZCTUVALDDONK-HQMSUKCRSA-N concanamycin A Chemical compound O1C(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@H](OC)[C@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](\C=C\C)[C@@H](C)[C@H](O[C@@H]2O[C@H](C)[C@@H](OC(N)=O)[C@H](O)C2)C1 DJZCTUVALDDONK-HQMSUKCRSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003083 cymarin Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 108010016290 deoxyribonucleoprotamine Proteins 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- GQIDSVPVVYHXAP-UHFFFAOYSA-N dihexyl decanedioate Chemical compound CCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCC GQIDSVPVVYHXAP-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- IAOSEBXZNXDPEE-UKRRQHHQSA-N elymoclavine Chemical compound C1=CC=C2[C@H]3C=C(CO)CN(C)[C@@H]3CC3=CN=C1[C]32 IAOSEBXZNXDPEE-UKRRQHHQSA-N 0.000 description 1
- DAVNRFCJMIONPO-UHFFFAOYSA-N elymoclavine Natural products C1=CC(C2C=C(CO)CN(C2C2)C)=C3C2=CNC3=C1 DAVNRFCJMIONPO-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- UJYGDMFEEDNVBF-XJUOHTAZSA-N ergocorninine Chemical compound C1=CC(C=2[C@@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-XJUOHTAZSA-N 0.000 description 1
- OWEUDBYTKOYTAD-MKTPKCENSA-N ergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@@H]1C=C2C3=CC=CC4=NC=C([C]34)C[C@H]2N(C)C1)C(C)C)C1=CC=CC=C1 OWEUDBYTKOYTAD-MKTPKCENSA-N 0.000 description 1
- HEFIYUQVAZFDEE-UHFFFAOYSA-N ergocristinine Natural products N12C(=O)C(C(C)C)(NC(=O)C3C=C4C=5C=CC=C6NC=C(C=56)CC4N(C)C3)OC2(O)C2CCCN2C(=O)C1CC1=CC=CC=C1 HEFIYUQVAZFDEE-UHFFFAOYSA-N 0.000 description 1
- NESVMZOPWPCFAU-ZPRCMDFASA-N ergosine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C)C2)=C3C2=CNC3=C1 NESVMZOPWPCFAU-ZPRCMDFASA-N 0.000 description 1
- NESVMZOPWPCFAU-UGTZLQJCSA-N ergosinine Chemical compound C1=CC(C=2[C@@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C)C2)=C3C2=CNC3=C1 NESVMZOPWPCFAU-UGTZLQJCSA-N 0.000 description 1
- BGHDUTQZGWOQIA-RKUMIMICSA-N ergovaline Natural products O=C(N[C@@]1(C)C(=O)N2[C@H](C(C)C)C(=O)N3[C@@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23 BGHDUTQZGWOQIA-RKUMIMICSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- FGDABGPSQJJTDH-ILKKLZGPSA-N ethyl (2s)-2,5-diaminopentanoate;dihydrochloride Chemical compound Cl.Cl.CCOC(=O)[C@@H](N)CCCN FGDABGPSQJJTDH-ILKKLZGPSA-N 0.000 description 1
- CZEPJJXZASVXQF-ZETCQYMHSA-N ethyl (2s)-2,6-diaminohexanoate Chemical compound CCOC(=O)[C@@H](N)CCCCN CZEPJJXZASVXQF-ZETCQYMHSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 1
- VUVZASHBYYMLRC-UHFFFAOYSA-N heptane-2,3-diol Chemical compound CCCCC(O)C(C)O VUVZASHBYYMLRC-UHFFFAOYSA-N 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- KNOSIOWNDGUGFJ-UHFFFAOYSA-N hydroxysesamone Natural products C1=CC(O)=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1O KNOSIOWNDGUGFJ-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- MHKWSJBPFXBFMX-UHFFFAOYSA-N iron magnesium Chemical compound [Mg].[Fe] MHKWSJBPFXBFMX-UHFFFAOYSA-N 0.000 description 1
- BIXXDPOEXJMBRN-UHFFFAOYSA-N iso-iridogermanal Natural products CC(CCC=C(C)C)C=CC(O)C(=CCCC1(C)C(CCCO)C(=C(C)/C=O)CCC1(C)O)C BIXXDPOEXJMBRN-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- CWPGNVFCJOPXFB-UHFFFAOYSA-N lapachol Chemical compound C1=CC=C2C(=O)C(=O)C(CC=C(C)C)=C(O)C2=C1 CWPGNVFCJOPXFB-UHFFFAOYSA-N 0.000 description 1
- SIUGQQMOYSVTAT-UHFFFAOYSA-N lapachol Natural products CC(=CCC1C(O)C(=O)c2ccccc2C1=O)C SIUGQQMOYSVTAT-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- JKAHWGPTNVUTNB-IXPVHAAZSA-N lergotrile Chemical compound C1=CC([C@H]2C[C@@H](CC#N)CN([C@@H]2C2)C)=C3C2=C(Cl)NC3=C1 JKAHWGPTNVUTNB-IXPVHAAZSA-N 0.000 description 1
- 229950007886 lergotrile Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003768 lonazolac Drugs 0.000 description 1
- XVUQHFRQHBLHQD-UHFFFAOYSA-N lonazolac Chemical compound OC(=O)CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 XVUQHFRQHBLHQD-UHFFFAOYSA-N 0.000 description 1
- JMCGQPHJXFUMBU-UHFFFAOYSA-N longikaurin B Natural products C=C1C(=O)C23C(O)C1CCC2C12CCCC(COC(=O)C)(C)C1C(O)C3(O)OC2 JMCGQPHJXFUMBU-UHFFFAOYSA-N 0.000 description 1
- JMCGQPHJXFUMBU-YEJWVSDBSA-N longikaurin b Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12CCC[C@](COC(=O)C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 JMCGQPHJXFUMBU-YEJWVSDBSA-N 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- BIXJFIJYBLJTMK-MEBBXXQBSA-N lysergol Chemical compound C1=CC(C2=C[C@@H](CO)CN([C@@H]2C2)C)=C3C2=CNC3=C1 BIXJFIJYBLJTMK-MEBBXXQBSA-N 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- KBMLJKBBKGNETC-UHFFFAOYSA-N magnesium manganese Chemical compound [Mg].[Mn] KBMLJKBBKGNETC-UHFFFAOYSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229950008693 mesulergine Drugs 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229940028370 methergine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Natural products C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 1
- KPNBUPJZFJCCIQ-LURJTMIESA-N methyl L-lysinate Chemical compound COC(=O)[C@@H](N)CCCCN KPNBUPJZFJCCIQ-LURJTMIESA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000739 myrtecaine Drugs 0.000 description 1
- BZRYYBWNOUALTQ-HOTGVXAUSA-N myrtecaine Chemical compound CCN(CC)CCOCCC1=CC[C@@H]2C(C)(C)[C@H]1C2 BZRYYBWNOUALTQ-HOTGVXAUSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 1
- 229950006286 pentrinitrol Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229950007140 proterguride Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- JWBVQJZXSQDXKU-UHFFFAOYSA-N sculponeatin C Natural products C1OC(=O)C2(C(C3=C)=O)CC3CC(O)C2C1(C12)C3OC2OCC1(C)CC3 JWBVQJZXSQDXKU-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- CTJJGIVJOBVMEO-UHFFFAOYSA-N tetraoctyl benzene-1,2,4,5-tetracarboxylate Chemical compound CCCCCCCCOC(=O)C1=CC(C(=O)OCCCCCCCC)=C(C(=O)OCCCCCCCC)C=C1C(=O)OCCCCCCCC CTJJGIVJOBVMEO-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical group O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3203—Polyhydroxy compounds
- C08G18/3206—Polyhydroxy compounds aliphatic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3225—Polyamines
- C08G18/3228—Polyamines acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
- C08G18/4269—Lactones
- C08G18/4277—Caprolactone and/or substituted caprolactone
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/44—Polycarbonates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6633—Compounds of group C08G18/42
- C08G18/6637—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/664—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6633—Compounds of group C08G18/42
- C08G18/6637—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6648—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3225 or C08G18/3271 and/or polyamines of C08G18/38
- C08G18/6651—Compounds of group C08G18/42 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3225 or C08G18/3271 and/or polyamines of C08G18/38 with compounds of group C08G18/3225 or polyamines of C08G18/38
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
- C08G18/751—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring
- C08G18/752—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group
- C08G18/753—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group
- C08G18/755—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group and at least one isocyanate or isothiocyanate group linked to a secondary carbon atom of the cycloaliphatic ring, e.g. isophorone diisocyanate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2230/00—Compositions for preparing biodegradable polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a kind of controllable degradation time, the adjustable medical degradable polyurethane of elongation at break, preparation method and applications, by adjusting the ratio of each component in polyurethane building-up process and selecting different chain extenders, PU performance can be controlled in very large range, such as PU degradation time, elongation at break, intensity, lubricity and hydrophilic and hydrophobic etc., according to regenerative medicine and the needs of the medicine equipment to implant, the medical degradable polyurethane of different performance can be selected.
Description
Technical field
The invention belongs to degradable biomaterial field, and in particular to a kind of degradation time is controllable, elongation at break is adjustable
Medical degradable polyurethane, preparation method and applications, by adjust in polyurethane building-up process the ratio of each component and
Different chain extenders is selected, PU elasticity and degradation time can be controlled in very large range, may be applicable to different soft and hard
The intervention implantation various medical products of human body of the bio-compatible of degree.
Background technology
Polyurethane (PU) full name is polyurethanes, is big containing carbamate (- NHC00-) group on main chain
The general designation of molecular compound, it be by organic diisocyanate or polyisocyanates and dihydroxy or polyol addition polymerization and
Into.Shown in typical PU chemical constitutions, the main polymer chain be by soft segment (soft segment) of the glass transition temperature less than room temperature and
Glass transition temperature forms higher than rigid chain segment (hard section) block of room temperature.In general, synthesized with polyethers or polyester diol,
The soft segment of polymer is formed, the segment glass transition temperature is low, and polarity is weak, the continuous phase of its constituent material, assigns PU elasticity and controls
Make PU lower temperature resistance, solvent resistance and weatherability etc.;And diisocyanate and the segment of chain extender reaction generation are hard section,
The hard section chain glass transition temperature generally constituted is high, and polarity is strong, the functional groups of-CO-NH- present in hard section, forms molecule interchain
Substantial amounts of hydrogen bond, interaction force is strong, exists with crystalline state, controls the performances such as PU intensity and heat resistance.PU hard section and
The crystallization of difference and hard section of the soft segment in polarity in itself causes their thermodynamically incompatible, and has spontaneous separation
Tendency, so hard section is easily clumped together to form microcell, be dispersed in the continuous phase of soft segment formation, form microphase-separated knot
Structure.The advantage of this material be can by design different soft, hard section structure, length and distribution, relative scale and
Change relative molecular mass etc., change PU performance, such as PU elasticity, modulus, intensity, extension at break in very large range
Rate, wearability, lubricity, hydrophilic and hydrophobic, biocompatibility and biological stability etc..
The polyaminoester microball surface texture that can degrade is similar to biomembrane, and this chain structure causes polyurethane to have certain life
Thing degradability, it is a kind of very promising regenerative medicine and the implantable medical material of human body.For obtain be adapted to different tissues or
The needs of implantation instrument, prepare neither too hard, nor too soft, technical barrier of the controllable polyurethane of degradation time into this area.
Domestic and international more literature research, which report polyurethane material, has good mechanical performance, biocompatibility, blood
The features such as compatibility and easy processing, it is very in fields such as slow releasing carrier of medication, medical surgical material, tissue engineering brackets
Promising degradable medical material, it is a kind of composition of excellent compound rest.Lot of domestic and international document all discloses preparation
It can drop the scheme of polyurethane, for example with 1,6- hexamethylene diisocyanates (HDI) be hard section, PCDL (PCDL)
The polyurethane synthesized for soft segment, ethyl ester of lysine hydrochloride (Lys-OEt) as chain extender;Using 1B as raw material, by L-
Converting carboxylate groups are ester group on lysine, and 1B diisocyanate (LDI) is synthesized under catalyst action and is divided respectively from different
The polyethylene glycol (PEG) of son amount or the polyurethane for being copolymerized to obtain to hydroxyethyl piperazine (HEP);By molecular weight be 2000 it is poly-
(6-caprolactone) dihydric alcohol (PCL) and LDI reaction generation prepolymers, then it is poly- with chain extender BDO (BDO) reaction synthesis
Urethane (PU) etc. than more typical patent document 200580014001.0 disclose it is a kind of with one-step method come the degradable poly for preparing
Urethane, wherein one-step method be by the raw material mixed onces such as oligomer polyol, polyisocyanates, chain extender and other auxiliary agents,
Cast, the method for reaction shaping, it is mainly used in generating the polyurethane elastomer of low modulus, and reaction product is difficult control, is obtained
The molecular weight of product is very wide;General industry production high performance polyurethane uses two step method, first using polyester or PPG
First and di-isocyanate reaction generates performed polymer, then generates polyurethane, obtained elastomer molecules with glycol or diamines chain extension
Structural arrangement is regular, and mechanical property is more preferable, reproducible, and product property is easily controlled, therefore, the present invention stretches to prepare fracture
The controllable high performance polyurethane of long rate, employs two step method to prepare.
Biodegradable stent includes high polymer material support and degradable metal support, wherein degradable high polymer material bag
Include:PLLA, PLA, PGA, PDO and PCL, wherein PLLA have preferable rigidity, pliability, resistance to stability and heat resistance,
Through being successfully applied to the coating material of metallic support and itself being prepared into support;Degradable metal timbering material have magnesium alloy and
Ferroalloy materials, wherein magnesium alloy materials are increasingly becoming the main flow that biodegradable stent is studied with its excellent processing characteristics.Due to
Alkaline environment and hydrogen caused by magnesium alloy materials degradation process, limit a large amount of uses;Due to blood vessel, tracheae and urethra etc. no
It is different to the performance requirement of used in tissue engineering biomaterial with the histoorgan at position, therefore obtain and a series of there are different mechanics
The biomaterial of performance, degradation property and processability etc. is most important, due to mechanical property existing for homogenous material with
And acid or alkali environment the problems such as causing internal aseptic inflammation caused by degraded, therefore, finding suitable composite high-molecular material, adopt
With more preferable support Design technique, compound rest has more preferable clinical value.
In degradable polyurethane preparation method in all open source literatures, all there is degradation speed in the hard section for obtaining polyurethane
The problem of slow, causing polyurethane to be wholly absent in vivo needs long time, greatly limit it in regenerative medicine
Use, to solve this technical barrier, prepare the controllable polyurethane of degradation time, our team are by grinding for many years
Study carefully, devise the amino acid diamine chain stretching agent with degradation site, successfully synthesize required for different tissues organ it is various can
Degradable polyurethane simultaneously realizes batch production, degradable polyurethane is developed into possibility for medical-related products.
The content of the invention
Medical drop the technical problem to be solved in the present invention is to provide a kind of degradation time is controllable, elongation at break is adjustable
Polyurethane, preparation method and applications are solved, it is different by adjusting the ratio of each component and selection in polyurethane building-up process
Chain extender, PU elasticity and degradation time can be controlled in very large range.
In order to solve the above technical problems, embodiments of the invention provide, a kind of degradation time is controllable, elongation at break is adjustable
Medical degradable polyurethane, using dithiothreitol (DTT), dihydric alcohol, two amino of band amino acid, derivative and its salt and one
One kind in the amino acids diamine that molecule dihydric alcohol is connected with two molecule amino acid with two ester bonds does chain extender, wherein ammonia
It is as follows that base acids diamine makees chain extender typical structure formula:
Wherein, P is dihydric alcohol, and X is 2-20 numeral;M and n is the one kind for commonly using 20 kinds of amino acid.
Wherein, described degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break, and soft segment can be
GA、LA、PDO(Lanthanum Isopropoxide), CL and PEG(200-2000)One or both of combination polymer, hard section choosing
From diisocyanate, it is chosen in particular from:1,6- hexamethylene diisocyanate(HDI), isoflurane chalcone diisocyanate(IPDI)、
Lysine methyl ester diisocyanate(LDI), ethyl ester of lysine diisocyanate(LDI), it is cis-cyclohexane diisocyanate, anti-
Formula-cyclohexane diisocyanate, Isosorbide-5-Nitrae-butane diisocyanate, butane diisocyanate, 1,2- ethane diisocyanate,
1,3- propane diisocyanate, 4,4 '-methylene-bis- (cyclohexyl isocyanate), IPDI, 2,4,
One or both of 4- trimethyls 1,6- hexane diisocyanates;Chain extender is using dithiothreitol (DTT), dihydric alcohol, two, band
The amino acids that amino acid, derivative and its salt of amino and a molecule dihydric alcohol are connected with two molecule amino acid with two ester bonds
One kind in diamine, it is as follows that the amino acids diamine makees chain extender typical structure formula:
Wherein P is dihydric alcohol, and X is 2-20 numeral, preferably 2-10;
Dihydric alcohol is chosen in particular from ethylene glycol, diethylene glycol (DEG), tetraethylene glycol, 1,3- propane diols, Isosorbide-5-Nitrae-butanediol, 1,5-PD, 1,
One or both of 6- hexylene glycols, 1,7- heptandiols, 1,8- ethohexadiols, 1,9- nonanediols, 1,10- decanediols;
M and n is the one kind for commonly using 20 kinds of amino acid, and wherein m and n can be the same or different.
Such as:Two molecule phenylalanines and a molecule 1,3 propane diols after esterification by obtaining by two ester bonds
The connected compound for possessing two ripple amino living, it is specific as follows:
Such as:Two molecule glycine and a molecule 1,3 propane diols pass through being connected by two ester bonds of being obtained after esterification
Possess the compound of two ripple amino living, it is specific as follows:
Similar citing is such as:Two molecule alanine and a molecule 1,3 propane diols after esterification by obtaining by two esters
The connected compound for possessing two ripple amino living of key, a molecule alanine and a molecule valine and a molecule 1,3 propane diols
By the compound that possesses two ripple amino living for obtaining being connected by two ester bonds after esterification, two molecule leucines with
One molecule 1,3 propane diols pass through the chemical combination that possesses two ripple amino living that obtains being connected by two ester bonds after esterification
Thing, isoleucine are gathered around with leucine and a molecule 1,3 propane diols by what is obtained after esterification by what two ester bonds were connected
There is the compound of two ripple amino living, two molecule phenylalanines and a molecule 1,3 propane diols are logical by what is obtained after esterification
The connected compound for possessing two ripple amino living of two ester bonds is crossed, two molecule proline and a molecule 1,3 propane diols pass through ester
Change the compound for possessing two ripple amino living being connected by two ester bonds obtained after reaction, two molecule tryptophans and a molecule
1st, 3 propane diols are by the compound that possesses two ripple amino living that obtains being connected by two ester bonds after esterification, two points
Sub- serine and a molecule 1,3 propane diols possess two ripple ammonia living by what is obtained after esterification by what two ester bonds were connected
The compound of base, two molecule cysteines and a molecule 1,3 propane diols after esterification by obtaining by two ester bond phases
The compound for possessing two ripple amino living even, two molecule methionine and a molecule 1,3 propane diols after esterification by obtaining
The compound for possessing two ripple amino living being connected by two ester bonds, two molecule asparagines and a molecule 1,3 propane diols
Pass through the compound for possessing two ripple amino living being connected by two ester bonds obtained after esterification, two molecule glutamine
Pass through the chemical combination for possessing two ripple amino living being connected by two ester bonds that is obtained after esterification with a molecule 1,3 propane diols
Thing, two molecule threonines and a molecule 1,3 propane diols possess two by what is obtained after esterification by what two ester bonds were connected
The compound of individual ripple amino living, a molecule aspartic acid and a molecule glutamic acid and a molecule 1,3 propane diols pass through esterification
The compound for possessing two ripple amino living being connected by two ester bonds obtained afterwards, include the combination and and one of various amino acid
Molecule 1,3 propane diols pass through the compound that possesses two ripple amino living that obtains being connected by two ester bonds after esterification.
The present invention also provides that a kind of degradation time is controllable, the preparation side of the adjustable medical degradable polyurethane of elongation at break
Method, to control the elongation at break of polyurethane, prepared using two step method, specific preparation method is as follows:
(1)The synthesis of a variety of degradation times and the degradable polyurethane of physical property
Soft segment is selected from GA, LA, PDO(Lanthanum Isopropoxide), CL and PEG(200-2000)One or both of polymerization
Thing, one kind in the one kind of hard section in diisocyanate, preferably LDI, IPDI, HDI or 1,3- propane diisocyanate,
Chain extender selection amino acid diamine, synthetic schemes are as follows:
Soft segment compound or composition and catalyst are placed in vacuum reaction bottle by inventory, are put into 70-140 DEG C of oil bath pan
Middle reaction 4-24 h obtain the polymer of line style, then weigh the di-isocyanate reaction 0.5-12h of proper proportion, use appropriate solvent
Dissolve or be directly added into amino acid diamine chain extension and connect, be evacuated and hermetically sealed bottleneck, be put into 0-120 DEG C of oil bath pan and react 2-
12h, obtain final product.
(2)Synthesis using amino acid as the degradable polyurethane of chain extender
Soft segment is selected from GA, LA, PDO(Lanthanum Isopropoxide), CL and PEG(200-2000)One or both of polymer group
Close, one kind in the one kind of hard section in diisocyanate, preferably LDI, IPDI, HDI or 1,3- propane diisocyanate,
Chain extender is selected from amino acid, derivative and its salt of two amino of band, amino acid hydrochloride salt is specifically included, such as lysine methyl ester two
Hydrochloride, ethyl ester of lysine dihydrochloride, cystine methyl esters dihydrochloride, cystine ethyl ester dihydrochloride, omithine methyl ester two
One kind in hydrochloride, ornithine ethyl ester dihydrochloride, synthetic schemes are as follows:
Soft segment compound or compound are combined, PDO, PEG or monomer CL, LA, GA is referred specifically to and catalyst is placed in by inventory
In vacuum reaction bottle, it is put into reaction 4-24 h in 70-140 DEG C of oil bath pan and obtains the polymer of line style, add diisocyanate
0.5-12h is reacted, the amino acids chain extender and triethylamine of proper proportion are dissolved or be directly added into appropriate solvent, is vacuumized simultaneously
Bottleneck is sealed, is put into 50-150 DEG C of oil bath pan and continues to react 2-24h, obtain final product.
(3)Soft segment is selected from the degradable polyurethane of PPDO or PDO and CL copolymers:
Soft segment is selected from PPDO, PDO and GA or CL and PDO(Its percentage by weight is 1:10-10:1)One or both of it is poly-
Compound combines, in the one kind of hard section in isocyanates, preferably LDI, IPDI, HDI or 1,3- propane diisocyanate
One kind, chain extender selection 1, ammediol, synthetic schemes are as follows:
Anhydrous PPDO, PDO and GA or CL and PDO and catalyst by proportion are placed in vacuum reaction bottle, are put into 120-140 DEG C
Oil bath pan in reaction 4-24 h obtain the polymer of line style, add the 1B di-isocyanate reaction 0.5- of proper proportion
12h, dissolved with appropriate solvent or be directly added into 1, ammediol, be put into vacuum reaction bottle, be evacuated and hermetically sealed bottleneck, be put into
2-24h is reacted in 50-150 DEG C of oil bath pan, obtains final product.
The one kind of the catalyst in tin class, zinc class or organic bismuth salt, dosage are the 0.001- of total amount of feeding
10wt%.
The tin catalyst is selected from organic tin catalyst dibutyltin dilaurylate, stannous octoate, dibutyl tin two
Laurate, dioctyl tin, dibutyl tin, dialkyl tin, dimaleate, two mercaptan tin alkyls, mercaptan dioctyl tin etc., it is excellent
Select stannous octoate.
The conventional bismuth class environmental protection catalyst assembly of the organic bismuth catalyst polyurethane industries among others, including bismuth neodecanoate, bay
Sour bismuth, isooctyl acid bismuth, bismuth naphthenate etc., preferably bismuth neodecanoate.
Degradation time of the present invention is controllable, the adjustable medical degradable polyurethane of elongation at break, further can be with
Chain extender or crosslinking agent are done from LTI or DTT, with the webbed cross-linked structure of shape, the polyurethane composition
The elongation at break of thing is higher than 300MPa, and elongation at break is in the range of 30%~700%, and reaction is selected from one of following manner:
(1)By the degradable polyurethane of two step synthetic method described in claim 3, two sulphur are added during second step chain extension
Threitol or LTI(Compare 1-30% with the weight of polyurethane), squeezed in twin-screw of the moisture less than 10ppm
Go out in machine and react 20 minutes, stirring polymerization extrusion, obtain the urethane composition with high elongation at tear;
(2)By the degradable polyurethane of two step synthetic method described in claim 3, contain during second step chain extension in moisture
Amount is poured into kneading machine or kneader in the environment of being less than 10ppm, is directly added into dithiothreitol (DTT) or the isocyanic acid of lysine three
Ester(Compare 1-30% with the weight of polyurethane)It is sufficiently stirred, normal-temperature reaction half an hour obtains having the described poly- of high elongation at tear
Urethane composition;
(3)By the degradable polyurethane of the two step synthetic method described in claim 3, added during second step chain extension
Anhydrous organic solvent(Tetrahydrofuran, dichloromethane or chloroform)Viscous solution is configured to, in moisture less than 10ppm's
DTT is directly added under environment(Dithiothreitol (DTT))Or LTI(Compare 1-30% with the weight of polyurethane), reactant
System's stirring or concussion mixing, vacuum drains organic solvent and obtains having the described poly- of high elongation at tear after normal-temperature reaction half an hour
Urethane composition.
The application of polyurethane of the present invention or its composition in medical embedded material is prepared, polyurethane of the present invention are made
To prepare the application in medical embedded material, the medical embedded material can be used alone, and can conform to other high polymer material systems
Used into compound, can be used for implantation equipment, implantable artificial organs, contact artificial organs, support, interposing catheter, people
Work skin, tissue engineering bracket and organ servicing unit, it is necessary to which further purifying removing has when as medical embedded material
Malicious monomer or organic solvent.
The poly- ammonia of medical degradable that a kind of elongation at break of the present invention is adjustable, the adjustable security of degradation time is good
Ester, can be compound with other degradation materials, and composite implantation material is made, specifically includes:Degradable high polymer material and it can drop
Metal material is solved, wherein the weight ratio of the polyurethane and the degradable metal material is in 0.1-99%:1%-99.9% scopes
Interior, the metal material includes iron of the purity more than 99.0%, purity is more than 99.0% magnesium, percentage by weight 1:0.01-10's
Mg-Fe alloy, percentage by weight 1:0.01-1 Mg-Zn based alloy, percentage by weight 1:0.01-1 magnesium calcium alloy, again
It is 1 to measure percentage:One or both of 0.01-0.1 Magnesium-aluminum alloys combine, preferably Mg-Fe alloy(Percentage by weight is preferred
1:0.01-0.1), Mg-Zn based alloy(Percentage by weight preferably 1:0.01-0.1), such as:Mg-Nd-Zn-Zr、Mg-Zn-Mn 、
Mg-Zn-Mn-Se-Cu alloys, Zn contents are 3.5wt%, and Mn contents are 0.5-1.0wt%, and Se contents are 0.4-1.0wt%,
Cu contents are 0.2-0.5wt%, Mg surpluses;Magnesium calcium alloy(Percentage by weight preferably 1:0.01-0.1), citing:Mg-Zn-
Ca-Fe, Magnesium-aluminum alloys(Percentage by weight is preferably 1:0.01-0.1, citing:Aluminium(Al):2.0-3.0wt.%, zinc(Zn):
0.5-1.0wt.%, manganese(Mn), Mg surpluses.
The weight ratio of the high polymer material is in 0.1-99% described in the polyurethane and high polymer material:1%-99.9% models
In enclosing, wherein high polymer material, selected from PLA, polycaprolactone, poly- to dioxa cyclohexanone and its copolymer (PPDO, PGA-
PPDO), gather to dioxa cyclohexanone(PPDO), it is PTMC, PLA-trimethylene carbonate copolymer, poly-
At least one of caprolactone-trimethylene carbonate copolymer, polyglycolic acid, Poly(D,L-lactide-co-glycolide, institute
The viscosity average molecular weigh for stating biodegradable high polymer material is 500-1,000,000.
The method of degradable metal compound in degradable implantation material of the present invention, comprises the following steps:
(1)Degradable metal material is worked out, carved, etched or cut into the decorative pattern or lath-shaped of needs, preferably decorative pattern diameter
For 0.01 to 3mm;
(2)Organic solvent is dissolved in by polyurethane of the present invention or with the composition of other high polymer materials(Selected from decane, tetrahydrochysene furan
Mutter, one kind in isoamyl acetate, hexane, dichloromethane, chloroform, cyclohexanone, dimethylformamide and heptane or two
Kind)In, coating material is made(The concentration of urethane composition described in coating is 5-50%);
(3)Will(2)The coating material of middle preparation repeatedly dip-coating, spray or film be made and overlay on(1)The metallic support table of middle preparation
Face, the compound rest with overlay film is made, the thickness of the overlay film is in the range of 0.001-1mm, preferably 0.01-0.5mm;
(4)Will(3)The overlay film frame of middle preparation is by dip-coating or spraying hydrophilic coating, and polishing grinding is into the biodegradable stent
Compound.
The method of wherein described biodegradable stent compound, one of following method can also be included:
(1)By magnesium alloy powder(Diameier scope is:10nm-1mm)It is (molten with organic solvent with the solution of urethane composition
Solve the urethane composition and be configured to the viscous solution of 20-90% concentration) it is well mixed, printed by 3D printer
Go out to need the support of diameter and wall thickness, the dry organic solvent of heated-air drying volatilization, obtain the biodegradable stent compound;
(2)3D printer is set into two feeding devices, magnesium alloy powder is added in a feeding device(Diameier scope
For:10nm-1mm), the solution of urethane composition is added in another feeding device(Percentage concentration is configured to organic solvent
For 20-90%), two kinds of materials print the support being sized with shape, heated-air drying after mixing in proportion during the charging
Volatilize dry organic solvent, obtains the biodegradable stent compound;
(3)3D printer sets two feeding devices, and magnesium alloy powder is added in a feeding device(Diameier scope is:
10nm-1mm), in another feeding device in proportion(1:0.1-10)Urethane composition and PLA are added, is mixed molten
Solution is in organic solvent, and it is 20-90% to be configured to percentage concentration with organic solvent, and two kinds of materials mix in proportion during charging
The support being sized with shape is printed after conjunction, the dry organic solvent of heated-air drying volatilization, it is compound to obtain the biodegradable stent
Thing;
(4)3D printer sets two feeding devices, and magnesium alloy powder is added in a feeding device(Diameier scope is:
10nm-1mm), high-temperature fusion prints support on demand, and Passivation Treatment is standby;In another feeding device in proportion(1:0.1-
10)Urethane composition and PLA are added, is then mixed and is dissolved in organic solvent, hundred are configured to organic solvent
It is 20-90% to divide concentration, and coating film is printed on support, the dry organic solvent of heated-air drying volatilization, obtains the biodegradable stent
Compound.
Wherein described organic solvent, selected from toluene, paraxylene, decane, isoamyl acetate, hexane, benzene, dichloromethane
Alkane, chloroform, cyclohexanone, ketone, dimethylformamide, heptane, dimethylamino formamide, tetrahydrofuran, petroleum ether, diformazan
One or both of sulfoxide, ethylene glycol terephthalate, preferably tetrahydrofuran, chloroform, toluene, paraxylene, second
One kind in isoamyl valerate or hexane.
Wherein described degradable polyurethane and metal material or the compound of high polymer material, its structure, composition and shape
Shape is applied to blood vessel, vein, oesophagus, biliary tract, trachea-bronchial epithelial cell, small intestine, large intestine, urethra, ureter or other close to tubular body
The fragment of passage, for example, as intravascular stent, trachea bracket, bronchial stent, urethra rack, Esophageal Stent, biliary tract rack,
Ureter bracket(Double J pipe), ureterostenosis section support, the support for small intestine, the support for large intestine, throat's implant,
Bypass manifold or ileal stoma.
Concrete application includes:Implantation equipment, implantable artificial organs, contact artificial organs, support, interposing catheter, with
And organ servicing unit, specifically include hone lamella, nail, spicule, bone rod, internal fixation of spine equipment, ligature, patella fracture fixator, bone wax,
Bone renovating material, aneurysm clips, silver brain clip, blood vessel anastomosis clamp(Device), shaping material, heart or tissue mending material, intraocular fill
Filling chock material, intrauterine device, neural sticking patch;Implantable artificial organs specifically includes:It is artificial esophagus, artificial blood vessel, artificial vertebral body, artificial
Joint, artificial urethra, artificial valve, artificial kidney, adopted breast, artificial skull, artificial jaw bone, artificial heart, artificial tendon, artitificial ear
Snail, artificial anus sealer;Touch artificial organs specifically includes:Artificial larynx, artificial skin, artificial cornea;Stented vessel is specific
Including:Support, prostate bracket, biliary tract rack, esophageal stents and ureter bracket;Organ servicing unit specifically includes:Plant
Enter formula audiphone, artificial hepaticsupport system;Extracorporal circulatory system and blood processing apparatus:Pump, Blood storing and filtering device, Micro- Bolt Filter, filter
Blood device, water filter(Ultrafiltration), bubble removal device, pump line, bloody path;Haemodialysis equipment, filtering device for blood dialysis, blood filtering
Device, blood purifying pipeline, dialysis bloody path, bloody path Plastic pump pipe, Arteriovenous puncture appliance, multi-layer planar type dialyzer, hollow fibre
Tie up dialyzer, doughnut pass filter, absorber, plasma separator, blood detoxification(Perfusion irrigates)Device, blood purification follow in vitro
Ring bloody path(Pipeline), intraoperative autotransfusion machine;Intervene equipment:Catheter in blood vessel:Intravascular angiography catheter, balloon expandable are led
Pipe, CVC, trocar peripheral catheters, miniature floating catheter, arteriovenous pressure catheter;Seal wire and pipe sheath, are specifically included:
Stiff guide wire, soft head seal wire, arteria renalis seal wire, micro-wire, push seal wire, superslide seal wire, arterial sheath, vein blood vessel sheath, micropuncture
Vagina vasorum;Embolism equipment, is specifically included:Filter, spring embolus, embolism microball, platinum microembolus, plugging device, intravenous injection
(IV), central veins (CV), vascular access, lung heat buffering balloon, angiography, angioplasty balloons, Urology Surgery, spy
Different conduit, pacemaker wires insulating barrier, artificial blood vessel, cardiac valves, heart-assist device, left ventricular assist device, sustainer
Aortic balloon, TAH, hemodialyzer, haemodialysis, artificial lung, blood oxygen exchanger, blood perfusion, blood filtering, blood
Flushing, artificial pancreas, breast implants, wound dressing, Facial reconstruction material, surgical adhesive, drug controlled release, artificial pipe
Road, the flowing for strengthening body fluid and excretion, contraceptive, penile prosthesis etc..
Further:Biodegradable stent composition disclosed by the invention, it can need to increase it according to the soft or hard of support peritonaeum
Its high polymer material, such as:PLA, polycaprolactone, gather to dioxa cyclohexanone and its copolymer (PPDO, PLA-PDO)
Gather to dioxa cyclohexanone(PPDO), PTMC, PLA-trimethylene carbonate copolymer, gather oneself in
Ester-trimethylene carbonate copolymer, polyglycolic acid, PLA-co-glycolic acid, polyether-ether-ketone, polyethylene pyrrole
Pyrrolidone and/or polyethylene glycol, poly- valerolactone, poly- ε-decalactone, polyactide, PGA, polyactide and PGA
Copolymer, poly- ε-caprolactone, poly butyric, poly butyric ester, poly- hydroxyl valerate, poly butyric ester-copolymerization-
Valerate, poly- (Isosorbide-5-Nitrae-dioxane -2,3- diketone), poly- (1,3- dioxane -2- ketone), poly- to dioxa
Cyclohexanone, polyanhydride (such as poly-maleic anhydride), poly- hydroxyl-metacrylate, fibrin, polybutylcyanoacrylate,
Polycaprolactone dimethylacrylate, poly- β-maleic acid, polycaprolactone butyl propyleneglycol acid esters, from oligomerization caprolactone two
Multi-block polymer, polyethylene glycol and the polybutylene terephthalate of alcohol and oligomerization dioxanone glycol)), poly- new penta
Lactone, polyglycolic acid carbonate, polycaprolactone-glycolide, poly- (γ-ethyl glutamate), poly- (DTH- imido
Base carbonic ester), poly- (DTE- copolymerization-DT- carbonic esters), poly- (bisphenol-A-iminocarbonic ester), poe, polyglycolic acid
It is carbonate, poly- trimethyl carbonate, poly- iminocarbonic ester, poly- (N- vinyl)-pyrrolidones, polyvinyl alcohol, poly-
Esteramides, dealing with alcohol polyester, polyphosphate, polyphosphazene, poly- [to carboxyphenoxy) propane], poly- hydroxypentanoic acid, polyanhydride, poly-
Polyurethane with amino acid residue, polyether ester (such as polyoxygenated in ethylene oxide-propylene oxide, flexibel polyurethane, main chain
Ethene), polyalkylene oxalate, poe and its copolymer, carrageenan, fibrinogen, starch, collagen, containing egg
One kind in white matter polymer, polyaminoacid, synthesis polyaminoacid, zein, the biodegradable high polymer material
Viscosity average molecular weigh be 500~1000000, preferred polylactic acid material, according to scaffold degradation needs, more preferably PLGA (LA:
G/A ratio is 1-3:1), such as:LA:GA ratio is 75:25;65:35 and 50:50 etc., polymer viscosity average molecular weigh is 5-
500000, preferred polymers viscosity average molecular weigh is 5-15 ten thousand, to improve the pliability of product, can also add nontoxic plasticizer, lemon
Lemon acid tributyl (TBC), tributyl 2-acetylcitrate (ATBC), trioctyl trimellitate (TOTM), tri trimellitate (810) ester, inclined benzene
Three sour glyceryl esters, tetraoctyl 1,2,4,5-benzenetetra-carboxylate, diethylene glycol dibenzoate, diethylene glycol dibenzoate, DPG hexichol first
One kind in acid esters, DOTP, DOTP, dihexyl sebacate, epoxidized soybean oil or two
More than kind.
Further:Degradable metal material disclosed by the invention is selected from, adding ingredient be iron, copper, zinc, cobalt, manganese, chromium, selenium,
Iodine, nickel, fluorine, molybdenum, vanadium, tin, silicon, strontium, boron, rubidium, arsenic, silver, a kind of or more Zhang Yuansus combination, its composition weight of magnesium alloy materials
Percentage is:Iron 0-2.0%, copper 0-2.0%, zinc 0-2.0%, cobalt 0-2.0%, manganese 0-2.0%, chromium 0-2.0%, selenium 0-2.0%, iodine 0-
2.0%th, nickel 0-2.0%, fluorine 0-2.0%, molybdenum 0-2.0%, vanadium 0-2.0%, tin 0-2.0%, silicon 0-2.0%, strontium 0-2.0%, boron 0-2.0%,
Rubidium 0-2.0%, silver 0.1~4%;Including:High purity iron(Purity is more than 99.0%), high purity magnesium(Purity is more than 99.0%), Mg-Fe alloy
(Percentage by weight is 1:0.01-10), Mg-Zn based alloy(Percentage by weight is 1:0.01-1), magnesium calcium alloy(Weight percent
Than for 1:0.01-1), Magnesium-aluminum alloys(Percentage by weight is 1:0.01-0.1)One or both of combination.Wherein magnesium iron closes
Gold(Percentage by weight preferably 1:0.01-0.1), Mg-Zn based alloy(Percentage by weight preferably 1:0.01-0.1), such as:Mg-Nd-
Zn-Zr, Mg-Zn-Mn, Mg-Zn-Mn-Se-Cu alloy, Zn contents are 3.5wt%, and Mn contents are 0.5-1.0wt%, and Se contains
Measure as 0.4-1.0wt%, Cu contents are 0.2-0.5wt%, Mg surpluses;Magnesium calcium alloy(Percentage by weight preferably 1:0.01-
0.1), such as:Mg-Zn-Ca-Fe, Magnesium-aluminum alloys(Percentage by weight is preferably 1:0.01-0.1, such as:Aluminium(Al):2.0-
3.0wt.%, zinc(Zn):0.5-1.0wt.%, manganese(Mn), Mg surpluses:
Further:Coating bracket disclosed by the invention, its preparation process are as follows:
(1)Degradable metal material is worked out, carved, etched or cut into the decorative pattern of needs;
(2)By polymer A:Degradable medical polyurethane material is dissolved in organic solvent, and coating material is made(Material concentration 5-
50%, specifically polyurethane is dissolved in tetrahydrofuran solution, is made into 10-30% solution);
(3)Will(1)The metallic support of middle preparation, passes through(2)Dip-coating, spraying either Electrospun are in rack surface repeatedly, at least
Part coating forms the pillar of grid or grid, coating compound rest is made, the material thickness of coating is preferably 0.01-3mm, excellent
Select between 0.01-0.5mm.
Peritonaeum support disclosed by the invention, its preparation process are as follows:
(1)Degradable metal material is worked out, carved, etched or cut into the decorative pattern or lath-shaped of needs;
(2)By polymer A:Degradable medical polyurethane material and polymer B:PLA(PLGA, LA:G/A ratio is 65:35,
Viscosity average molecular weigh is 8-10 ten thousand)By 1:Film, preferably thickness 0.01-3mm, 0.1- is made in organic solvent in 2 mixed dissolutions
1mm;
(3)Will(1)The metallic support of middle preparation, passes through(2)Overlay film frame is made in metal material surface in the film roll of preparation;
(4)Will(3)The composite of middle preparation passes through dip-coating or spraying hydrophilic coating(Such as chitosan, hyaluronic acid, glue
Aqueous solution etc. is made in former, cellulose), dry, polish, be polished to overlay film frame.
Support disclosed by the invention, is prepared with 3D printing technique:
(1)One of preparation method:By magnesium alloy powder(Diameier scope is:10nm-1mm, preferably 1um-100um)With that can drop
Solving medical polyurethane material solution, (organic dissolution dissolves, and is configured to the viscous solution of 20-90% percentage concentrations, and preferably 30-50% is dense
The tetrahydrofuran or chloroform soln of degree) it is well mixed, the support for needing diameter and wall thickness is printed by 3D printer, heat
The dry organic solvent that volatilizes is air-dried both to obtain;
(2)The two of preparation method:3D printer sets two feeding devices, and magnesium alloy powder is added in a feeding device(Powder
Last diameter range is:10nm-1mm, preferably 1um-100um), degradable medical polyurethane material is added in another feeding device
Solution(It is 20-90% to be configured to percentage concentration with organic solvent, and preferably the tetrahydrofuran of 30-50% concentration or chloroform are molten
Liquid), two kinds of materials print the support being sized with shape after mixing in proportion during the charging, heated-air drying volatilizes
Organic solvent both obtained;
(3)The three of preparation method:3D printer sets two feeding devices, and magnesium alloy powder is added in a feeding device(Powder
Last diameter range is:10nm-1mm, preferably 1um-100um), degradable medical polyurethane material is added in another feeding device
With PLA in proportion(1:0.1-10)For mixed dissolution in organic solvent, it is 20- to be configured to percentage concentration with organic solvent
90%, the preferred tetrahydrofuran or chloroform soln of 30-50% concentration, after two kinds of materials mix in proportion during charging
The support being sized with shape is printed, heated-air drying volatilizes organic solvent and both obtained;
(4)The four of preparation method:3D printer sets two feeding devices, and magnesium alloy powder is added in a feeding device(Powder
Last diameter range is:10nm-1mm, preferably 1um-100um), high-temperature fusion prints support on demand, and Passivation Treatment is standby;Separately
Degradable medical polyurethane material and PLA are added in one feeding device in proportion(1:0.1-10)Mixed dissolution is in organic
In solvent, it is 20-90% to be configured to percentage concentration with organic solvent, and coating film is printed on support, and heated-air drying volatilizes organic
Solvent both obtained.
Wherein magnesium alloy powder(Diameier scope is:10nm-1mm, preferably 1um-100um), can be dropped according to support
The requirement for solving the time is passivated processing according to disclosed various methods, forms corrosion resistant nontoxic conversion film.
When preparing intravascular stent, on the bare bracket surface handled well, the crosslinking by anticoagulant composition by glutaraldehyde
Anticoagulant composition is crosslinked and fixed by agent, and hemostatic composition can select hirudin, Heparan sulfate and its derivative such as complete
Devulcanization and N- acetylated-heparin devulcanization and N- acetylated-heparin again again, the anti-freezing of blood clotting will not be activated by, which being prepared into, applies
Layer;
When needing to prepare the support of degradation time length, corrosion resistant nontoxic conversion can be formed in degradable magnesium alloy surface passivation
Film, conventional have phosphate conversion embrane method, phytic acid conversion film, rare-earth salts conversion embrane method and an organic matter conversion embrane method, or
Bare bracket surface carries out fluorination treatment, and specific method is will to be polished for undressed biodegradable magnesium-alloy stent, in matter
It is that 12~96h is soaked in 20~40% hydrofluoric acid to measure percentage.
Biodegradable stent composition of the present invention, it is characterised in that, can be in polyurethane material according to clinical needs
Middle addition is commercially available or disclosed polypeptide, albumen and active component, including antiproliferative, anti-migration, anti-angiogenesis,
Anti-inflammatory, anti-inflammatory, cell growth inhibition, cytotoxicity or the antithrombotic medicine with physiologically active, such as Xi Luomo
Department, everolimus, Elidel, alkeran, ifosfamide, Trofosfamide, Chlorambucil, bendamustine, growth hormone release inhibiting hormone,
Tacrolimus, ROX, daunomycin, ascosin, Ba Foluo mycins, Luo Mositing, endoxan, Estramustine, reach
Carbazine, Abboticine, medecamycin, caspase, canavalin, Clarith, troleandomycin, catharanthine, length
Spring new alkali, eldisine, vinorelbine, Etoposide, Teniposide, Nimustine, BCNU, busulfan, procarbazine,
Treosulfan, Temozolomide, phosphinothioylidynetrisaziridine, Doxorubicin, Aclarubicin, epirubicin, mitoxantrone, idarubicin, it is rich come it is mould
Element, mitomycin C, dactinomycin D, methopterin, fludarabine, fludarabine -5 '-dihydrogen orthophosphate, Cladribine, mercapto
Purine, thioguanine, cytarabine, fluorouracil, gemcitabine, capecitabine, polyenoid taxol, carboplatin, cis-platinum, Ao Shali
Him is cut down in platinum, rosuvastatin, Atorvastatin, Pravastatin, Pitavastatin, folimycin, cerivastatin, Simvastatin, Lip river
Spit of fland, Fluvastatin, amsacrine, Irinotecan, Hycamtin, hydroxycarbamide, Miltefosine, Pentostatin, Aldesleukin, Wei Jia
Acid, asparaginase, Pegaspargase, arimidex, Exemestane, Letrozole, formestane, aminoglutethimide, Bromerguride, bromine wheat
Square ring peptide, elymoclavine, ergocristine, ergocritinine, Eg, ergonovine, ergosine, ergosinine, wheat
The different new alkali in angle, ergotamine, ergotaminine, ergovaline, ergocorninine, ergocryptine, ergokryptinine, ergometrine,
Lergotrile, lisuride, lysergol, ergotic acid, adriamycin, Azithromycin, spiramvcin, cepharanthine, 8- α-ergot
Spirit, dimethyl ergoline, agroclavine, 1- pi-allyls lisuride, 1- pi-allyls Terguride, lysergic acid amides, ergot
Diethylammonium salt, isolysergic acid, isolysergamide, isolysergic acid diethylamine, mesulergine, Distaval, (5- isoquinolin sulphonyl
Base) homopiperazine, cyclosporin, the ω of inhibitors of smooth muscle cell proliferation 2, liserdol, methergine, two methergolines are new
Alkali, pergolide, Proterguride and Terguride, celecoxib, ebomycin A and B, mitoxantrone, imuran,
Mycophenolate, Antisense c-myc, antisense b-myc, betulic acid, camptothecine, wooden Pa Fosite, melanocyte promote hormone, work
Property PROTEIN C, interleukin 1-β-inhibitor, β-lapachol, podophyllotoxin, betulin, the 2- ethyls hydrazine of podophyllic acid, not
Plast booth, peg-interferon α-2b, Lenograstim, Filgrastim, Dacarbazine, basiliximab, daclizumab, choosing
Select albumen, cetp inhibitors, cadherins, cell factor inhibitors, Transitional cell carcinomas inhibitor, thymosin extrasin
α -1, fumaric acid and its ester, its salts, Tacalcitol, lapachol, nuclear factor kappaB, angiopeptin, Ciprofloxacin, fluorine
Xi Ting, suppress the monoclonal antibody of muscle cell proliferation, be human/bovine basic fibroblast growth factor antagonist, probucol, preceding
Row parathyrine, 1,11- escoparone -6- ketone, 1- hydroxyl -11- methoxy coumarin -6- ketone, scopolactone,
Colchicin, nitric oxide donors, tamosifen, Fosfestrol, Medroxyprogesterone, cycloprovera, oestradiol benzoate, song
Ni Site, Verapamil, staurosporine, β-estradiol, α-estradiol, estriol, oestrone, ethinyloestradiol, EGFR-TK suppression
Preparation, Ciclosporin A, taxol and its derivative, synthesis and by natural origin obtain carbon suboxide macrocyclic oligomer and
Its derivative, Chemiartrol, rantudil, Diclofenac, lonazolac, dapsone, adjacent carbamyl-phenoxy group-acetic acid,
Lidocaine, Ketoprofen, mefenamic acid, tumor chalone, Avastin, HCQ, Anranofin, sodium aurothiomalate, Austria
Sha Xiluo, celecoxib, β-sitosterol, Ademetionine, myrtecaine, laureth 9, vanillylnonanamide, a left side
Menthol, benzocainum, Aescin, Ellipticine, demecolcine, CA-E, Yin Dannuoxin
(indanocine), nocodazole, piroxicam, Meloxicam, chloroquine diphosphate, penicillamine, S100 albumen, Bacitracin, glass
Glass binding protein precursor receptor antagonist, azelastine, guanidine radicals cyclase stimulators, the tissue depressant of metalloproteinases 1 and 2,
Free nucleic acid, the nucleic acid for being incorporated to viral mediator, DNA and ribonucleic acid fragments, plasminogen activator inhibitor
1st, plasminogen activator inhibitor 2, ASON, vascular endothelial growth factor receptor inhibitors, insulin-like growth factor
Acetylated-heparin, tissue are fine again by son 1, the activating agent from antibiotic group, penicillins, antithrombotic agent, desulfurization and N-
Plasminogen-activating dose, GpIIb/IIIa platelet membranes acceptor, factor Xa inhibitor antibody, heparin, hirudin, r- hirudins,
D- phenylalanine-proline-arginine-chloromethane ketone (D-phenylalanyl-L-prolyl-L-arginine
Chloromethyl ketone), acetylcholinesteraseinhibitors inhibitors, sulfoprotein enzyme inhibitor, prostacyclin, Vapiprost,
Interferon-' alpha ', β and γ, histamine antagonist, serotonin blockers, apoptosis inhibitor, apoptosis regulators, nucleoprotamine,
Sodium salt, prourokinase, streptokinase, warfarin and the urokinase of 2- methyl thiazolium oxazolidine -2,4- dioctyl phthalate, vasodilator,
Growth factor antagonist, Halofuginone, nifedipine, tocopherol, vitamin B1, B2, B6 and B12, the leaf in blood platelet source
Acid, molsidomine, Tea Polyphenols, L-Epicatechin gallate, nutgall catechin gallic acid ester, leflunomide, A Nabai are stagnant
Element, Etanercept, procainamide, retinoic acid, quinindium, Dimpyramidum Dimpyramidum, flecainide, Propafenone, Suo Taluo
That, amiodarone, the steroids of natural or synthetic acquisition, Inonotus obliquus alcohol, Ma Kuier glucosides A, SASP, rely on primary glycosides,
It is triamcinolone, mutamycin 6, suede trailing plants mushroom glucoside, Man Suoning, magpie kidney glucoside, hydrocortisone acetate, betamethasone, dexamethasone, non-
Steroids anti-inflammatory material, antifungal, antiprotozoal, natural terpenoids, 4,7- epoxide rings anisomelic acid, drought
Ground chrysanthemum terpene B1, B2, B3 and B7, glucosides tobeimosides, anti-dysentery Java brucea alcohol A, B and C, anti-dysentery yatanoside C, Java brucea are bitter
Glycosides N and P, isodexyelephantopin, support careless lactone A and B, dihydroxypropyltheo-pylline A, B, C and D, Amethystoidin A white flower
A and B, Nitidine Chloride, 12- β-hydroxyl gestation diene -3,20- diketone, longikaurin B, sculponeatin C, plan lack
Rabdosia amethystoides terpene, Rabdosia racemosa terpene A and B, Chinese yew element A and B, thunder cough up Buddhist nun's alcohol), Triptolide, ursolic acid, jatamasic acid A,
Isoiridogermanal, Variable-leaved Mayten alcohol, Guan Qiu grapheme A, cymarin, strophanthin, aristolochic acid, aminopterin-induced syndrome, hydroxyl
Amine petrin, Anemonin, protoanemonin, jamaicin, chlorination Qie Libai elements, cicutexin, mufangchine, three-bristle cudrania tree isoflavones A,
The salt of turmeric, Dihydronitidine, ginkgol, bilobol, gingko eo-acid etc. and above-mentioned activating agent, hydrate, solvate,
Enantiomer, racemic compound, enantiomer mixture, diastereoisomer mixture and its mixture.
Wherein described implantation class medical product further comprises contrast agent, and the contrast agent selects selected from contrast agent:Often
Use radiocontrast medium(Positive and negative contrast medium)Extremely analog, generally go back zirconium, barium, Dian, Manganese, iron, lanthanum, cerium, praseodymium, etc.
With reference to or form complexed ionic species, preferably baric or iodine contrast agent, more preferably in zirconium dioxide, barium sulfate and Operand
One kind.
The above-mentioned technical proposal of the present invention has the beneficial effect that:The present invention is by adjusting each group in polyurethane building-up process
Point ratio and the different chain extender of selection, can control PU performance in very large range, such as PU degradation time, disconnected
Elongation, intensity, lubricity and hydrophilic and hydrophobic etc. are split, can be according to regenerative medicine and the need of the medicine equipment to implant
Want, select the polyurethane of different performance.
Embodiment
To make the technical problem to be solved in the present invention, technical scheme and advantage clearer, below in conjunction with specific implementation
Example is described in detail.
Scheme one:The synthesis of the degradable polyurethane of a variety of degradation times and elongation at break
Note:The raw material advanced processing used in the present embodiment is less than 10ppm to water content, standby.
Embodiment 1
9.0g 6-caprolactones, 3.0g PEG-600, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, add
Enter in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, and sealed under vacuumized conditions
Vacuum reaction bottleneck, it is put into 140 DEG C of oil bath pan and reacts 24 h and obtain the polymer of line style.It is different that 2gL- lysines two are weighed again
Cyanate and 0.6g glycine diamines, are evacuated and hermetically sealed bottleneck, are put into 50 DEG C of oil bath pan and react 4h, finally produced
Thing.
Embodiment 2
9.0g 6-caprolactones, 0.5g PEG-600, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, add
Enter in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, and sealed under vacuumized conditions
Vacuum reaction bottleneck, it is put into reaction 18h in 140 DEG C of oil bath pan and obtains the polymer of line style.2.6gL- lysines two are weighed again
Isocyanates and 0.68g phenylalanine diamines, are evacuated and hermetically sealed bottleneck, are put into 70 DEG C of oil bath pan and react 8h, obtain most
End-product.
Embodiment 3
The lactide of 9.0g ε-, 1.0g PEG-200, new certain herbaceous plants with big flowers acid bismuth are weighed respectively(The 1.0wt% of total amount)As catalyst, add
In vacuum reaction bottle, a magnetic stir bar is added, is vacuumized/inflated with nitrogen circulates 3 times, and is sealed under vacuumized conditions true
Sky reaction bottleneck, is put into 130 DEG C of oil bath pan and reacts 24 h and obtain the polymer of line style.The isocyanide of 2gL- lysines two is weighed again
Acid esters and 0.7g cysteine diamines, are evacuated and hermetically sealed bottleneck, are put into 70 DEG C of oil bath pan and react 4h, finally produced
Thing.
Embodiment 4
3.0g ε-lactide, 6.0g 6-caprolactones, 1.5gPEG-400, stannous octoate are weighed respectively(The 0.03wt% of total amount)Make
For catalyst, add in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, and it is true in taking out
Vacuum reaction bottleneck is sealed under empty condition, is put into 140 DEG C of oil bath pan and is reacted 6 h and obtain the polymer of line style.Weigh again
3gBDI and 1.5g leucine diamines, is evacuated and hermetically sealed bottleneck, is put into 50 DEG C of oil bath pan and reacts 4h, obtains final product.
Embodiment 5
2.0g 6-caprolactones, 6.0gPDO, 3.0g PEG-600, stannous octoate are weighed respectively(The 0.03wt% of total amount)As urging
Agent, add in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, and in vacuumizing bar
Vacuum reaction bottleneck is sealed under part, is put into 140 DEG C of oil bath pan and is reacted 24 h and obtain the polymer of line style.9gL- is weighed again to rely
Propylhomoserin diisocyanate and 3g proline diamines, are evacuated and hermetically sealed bottleneck, are put into 100 DEG C of oil bath pan and react 12h, obtain
Final product.
Embodiment 6
9.0g 6-caprolactones, 3.0g PEG-600, You Ji bismuth salt are weighed respectively(The 3wt% of total amount)As catalyst, add true
In empty reaction bulb, a magnetic stir bar is added, vacuumize/inflated with nitrogen circulates 3 times, and seal vacuum under vacuumized conditions
Bottleneck is reacted, is put into 150 DEG C of oil bath pan and is reacted 14 h and obtain the polymer of line style.12gIPDI and 2.0g first sulphur is weighed again
Propylhomoserin diamines, is evacuated and hermetically sealed bottleneck, is put into 60 DEG C of oil bath pan and reacts 24h, obtains final product.
Embodiment 7
9.0g 6-caprolactones, 1.0gPDO, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, vacuum is added
In reaction bulb, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum it is anti-
Bottleneck is answered, is put into 140 DEG C of oil bath pan and reacts 18 h and obtain the polymer of line style, add 20ml DMSO or DMF dissolving reaction
Product, then 5gL- lysine diisocyanates and 2g valine diamines are weighed, bottleneck is evacuated and hermetically sealed, is put into 50 DEG C of oil bath
4h is reacted in pot, obtains final product.
Embodiment 8
8.0g 6-caprolactones, 2.0g GA, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, vacuum is added
In reaction bulb, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum it is anti-
Bottleneck is answered, is put into 120 DEG C of oil bath pan and is reacted 20 h and obtain the polymer of line style.6gL- lysine diisocyanates are weighed again
With 2g hydroxyl proline diamines, bottleneck is evacuated and hermetically sealed, is put into 70 DEG C of oil bath pan and reacts 4h, obtain final product.
Embodiment 9
8.0g PDO, 0.5gGA, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, vacuum reaction bottle is added
In, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum reaction bottle
Mouthful, it is put into reaction 12h in 90 DEG C of oil bath pan and obtains the polymer of line style, weighs 3gHDI and add in reaction bulb, react 2h, then
1g alanine diamines is added, bottleneck is evacuated and hermetically sealed, is put into 50 DEG C of oil bath pan and reacts 4h, obtain final product.
Embodiment 10
8.0g 6-caprolactones, 0.5g PEG-1000, organic bismuth salt are weighed respectively(The 0.3wt% of total amount)As catalyst, add
In vacuum reaction bottle, a magnetic stir bar is added, is vacuumized/inflated with nitrogen circulates 3 times, and is sealed under vacuumized conditions true
Sky reaction bottleneck, it is put into reaction 15h in 100 DEG C of oil bath pan and obtains the polymer of line style;Weigh the isocyanic acid of 3gL- lysines two
Ester is added in reaction bulb, reacts 2h, and the phenylalanine diamines for adding 1.5g is put into vacuum reaction bottle, is evacuated and hermetically sealed bottle
Mouthful, it is put into 40 DEG C of oil bath pan and reacts 4h, obtains final product.
Embodiment 11
9.00g 6-caprolactones, 3.00g PEG-600 are weighed respectively, and stannous octoate is added in test tube, added as catalyst
One magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, and test tube mouth sealed under vacuumized conditions, it is put into 140 DEG C of oil
24 h are reacted in bath and obtain the polymer of line style, then weigh 2gBDI and 0.8gBDO, are put into test tube, vacuumize simultaneously tube sealing
Mouthful.It is put into 70 DEG C of oil bath pan and reacts 12h, obtains final product.
Embodiment 12
Weigh 1gLA, 9gGA, 1g1,3 propane diols, stannous octoate(The 0.03wt% of total amount)As catalyst, a magnetic is added
Power stirrer, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal test tube mouth, be put into 110 DEG C of oil bath pan
React 12 h and obtain the polymer of line style, weigh 3gL- lysine diisocyanates and 0.6g1,3 propane diols, be put into vacuum reaction
In bottle, vacuumize/inflated with nitrogen circulates and is evacuated and hermetically sealed bottleneck 3 times, it is put into 70 DEG C of oil bath pan and reacts 4h, is finally produced
Thing.
Embodiment 13
Weigh poly- (hexa-methylene carbonic ester) glycol of 10g(Viscosity average molecular weigh 2000-3000), organic bismuth salt(Total amount
0.03wt%)As catalyst, a magnetic stir bar is added, weighs 3gL- lysine diisocyanates and 0.6g alanine
Diamines, it is put into vacuum reaction bottle, vacuumize/inflated with nitrogen circulates and is evacuated and hermetically sealed bottleneck 3 times, it is put into 70 DEG C of oil bath pan
4h is reacted, vacuum reaction bottle is taken out and is cooled to room temperature, obtains final product.
Embodiment 14
6.0gPDO, 3.0g PEG-600, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, vacuum is added
In reaction bulb, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum it is anti-
Answer bottleneck, be put into 100 DEG C of oil bath pan react 16h obtain the polymer of line style, then weigh 2.4gIPDI, 0.6gHDI and
0.6g glycine diamines, is put into vacuum reaction bottle, is evacuated and hermetically sealed bottleneck, is put into 70 DEG C of oil bath pan and reacts.
Embodiment 15
Obtained polyurethane will be reacted above to be dissolved with chloroform, is paved into thick 0.5mm film, is cut into 1cm × 5cm film
Block, test fracture productivity ratio are simultaneously placed in PBS solution simultaneously, 37 degree of incubations, observe degradation experiment, as a result as follows:
Scheme two:Synthesis using amino acid as the degradable polyurethane of chain extender
Embodiment 16
9.0g 6-caprolactones, 3.0g PEG-600, You Ji bismuth salt are weighed respectively(The 3wt% of total amount)As catalyst, add true
In empty reaction bulb, a magnetic stir bar is added, vacuumize/inflated with nitrogen circulates 3 times, and seal vacuum under vacuumized conditions
Bottleneck is reacted, reaction 14h in 130 DEG C of oil bath pan is put into and obtains the polymer of line style.2gIPDI and 2.0g lysines are weighed again
Methyl esters dihydrochloride and triethylamine, are evacuated and hermetically sealed bottleneck, are put into 120 DEG C of oil bath pan and react 14h, are finally produced
Thing.
Embodiment 17
9.0g 6-caprolactones, 0.5gPDO, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, vacuum is added
In reaction bulb, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum it is anti-
Bottleneck is answered, is put into 130 DEG C of oil bath pan and is reacted 18 h and obtain the polymer of line style.20ml DMSO dissolving reaction products are added,
3gL- lysine diisocyanates and 2g ethyl ester of lysine dihydrochloride and triethylamine are weighed again, is evacuated and hermetically sealed bottleneck, are put
Enter in 130 DEG C of oil bath pan and react 4h, obtain final product.
Embodiment 18
8.0g 6-caprolactones, 2.0gGA, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, it is anti-to add vacuum
Answer in bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, and seal vacuum reaction under vacuumized conditions
Bottleneck, it is put into 120 DEG C of oil bath pan and reacts 24 h and obtain the polymer of line style.Weigh again 6gL- lysine diisocyanates and
2g cystine methyl esters dihydrochlorides and triethylamine, are evacuated and hermetically sealed bottleneck, are put into 120 DEG C of oil bath pan and react 4h, obtain
Final product.
Embodiment 19
12.0g PDO, 0.5gLA, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, vacuum reaction is added
Bottle in, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum reaction bottle
Mouthful, it is put into reaction 24h in 100 DEG C of oil bath pan and obtains the polymer of line style, weighs 3gHDI and add in reaction bulb, react 2h, then
1g omithine methyl esters dihydrochloride and triethylamine are added, bottleneck is evacuated and hermetically sealed, is put into 100 DEG C of oil bath pan and reacts 4h,
Obtain final product.
Embodiment 20
8.0gPDO, 0.5gGA, organic bismuth salt are weighed respectively(The 0.3wt% of total amount)As catalyst, vacuum reaction bottle is added
In, add a magnetic stir bar, vacuumize/inflated with nitrogen circulate 3 times, and under vacuumized conditions seal vacuum reaction bottle
Mouthful, it is put into 90 DEG C of oil bath pan and reacts 24 h and obtain the polymer of line style.The addition of 3gL- lysine diisocyanates is weighed again
In reaction bulb, 2h is reacted, the phenylalanine diamines for adding 1.5g is put into vacuum reaction bottle, is evacuated and hermetically sealed bottleneck, puts
Enter in 100 DEG C of oil bath pan and react 4h, obtain final product.
Scheme three:Soft segment is selected from the degradable polyurethane of PPDO, PDO and GA or PDO and CL copolymers:
Embodiment 21
9.00g PPDO glycol is weighed respectively(Molecular weight 2000), 3gLDI and 0.6g1, ammediol, stannous octoate(Total amount
0.03wt%)As catalyst, add in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulation 3
It is secondary, it is put into reaction 24h in 100 DEG C of oil bath pan and obtains final product.
Embodiment 22
Weigh 16gPDO and 1gGA to be placed in vacuum reaction bottle, be put into reaction 24h in 140 DEG C of oil bath pan and obtain the polymerization of line style
Thing, 3g HDI reaction 0.5h are added, 1g 1, ammediol is added, is put into vacuum reaction bottle, is evacuated and hermetically sealed bottleneck, put
Enter in 120 DEG C of oil bath pan and react 24h, obtain final product.
Embodiment 23
Weigh 6gPDO and 1gCL to be placed in vacuum reaction bottle, be put into reaction 12h in 130 DEG C of oil bath pan and obtain the polymerization of line style
Thing, 2g BDI reaction 4h are added, 0.5g1, ammediol is added, is put into vacuum reaction bottle, is evacuated and hermetically sealed bottleneck, be put into
24h is reacted in 110 DEG C of oil bath pan, obtains final product.
Embodiment 24
Weigh 9gGA and 1gCL to be placed in vacuum reaction bottle, be put into 120 DEG C of oil bath pan, add dimethylbenzene, evaporation removes one
Partial solvent, reaction 16h obtain the polymer of line style, add 2g LDI reaction 12h, add 1g1, ammediol, be put into 120 DEG C
Oil bath pan in, react 12h under vacuum state, obtain final product.
Embodiment 25
9g Lanthanum Isopropoxides, 2g PEG-400, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst, add
In vacuum reaction bottle, a magnetic stir bar is added, is vacuumized/inflated with nitrogen circulates 3 times, and is sealed under vacuumized conditions true
Sky reaction bottleneck, it is put into reaction 18h in 100 DEG C of oil bath pan and obtains the polymer of line style.2gLDI and 0.6g1,3- third are weighed again
Glycol, it is put into vacuum reaction bottle, is evacuated and hermetically sealed bottleneck, is put into 100 DEG C of oil bath pan and reacts 4h, finally produced
Thing.
Method four:With DTT or LTI end-blockings or the polyurethane of crosslinking
In the second step of above example, when adding diisocyanate or chain extender progress chain extension, it is different to add 1B three
Cyanate/DTT is blocked, and prepares the polyurethane of high elongation at tear, and wherein preparation method is exemplified below:
One of method:The polymer diol obtained by method provided in an embodiment of the present invention, it is less than 10ppm ring in moisture
Reacted 20 minutes in double screw extruder extruder under border, stirring polymerization extrusion, the polyurethane for obtaining high elongation at tear is fine
Dimension;
The two of method:The polymer diol obtained by method provided in an embodiment of the present invention, it is less than 10ppm ring in moisture
Poured under border in kneading machine or kneader, be directly added into 1B triisocyanate/DTT and be sufficiently stirred, normal-temperature reaction half
Hour both obtained;
The three of method:The polymer diol obtained by method provided in an embodiment of the present invention, add anhydrous organic solvent and be configured to
Viscous solution, in the environment of moisture is less than 10ppm, it is directly added into 1B triisocyanate/DTT, reaction system
Stirring or concussion mixing, vacuum is drained organic solvent and both obtained after normal-temperature reaction half an hour, and wherein organic solvent is selected from toluene, to two
Toluene, decane, isoamyl acetate, hexane, benzene, dichloromethane, chloroform, 1,4 cyclohexanone, ketone, dimethylformamide, heptan
One or both of alkane, dimethylamino formamide, tetrahydrofuran, petroleum ether, dimethyl sulfoxide, ethylene glycol terephthalate,
It is preferred that one or both of tetrahydrofuran, dichloromethane, chloroform and 1,4 cyclohexanone are combined.
Embodiment is exemplified below:
Embodiment 26
6.00g 6-caprolactones and 3.00g Lanthanum Isopropoxides, 1.00gPEG300, organic bismuth salt are weighed respectively(Total amount
0.03wt%)As catalyst, add in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulation 3
It is secondary, and vacuum reaction bottleneck is sealed under vacuumized conditions, it is put into 140 DEG C of oil bath pan and reacts 24 h and obtain the polymerization of line style
Thing.5gL- lysine diisocyanates and 1.0g tetraethylene glycols are weighed again, are put into vacuum reaction bottle, are evacuated and hermetically sealed bottleneck,
Be put into 70 DEG C of oil bath pan and react 4h, obtain final product, moisture be less than 10ppm in the environment of pour into kneading machine or
In person's kneader, it is directly added into 2.0gL- LTIs and is sufficiently stirred, normal-temperature reaction half an hour both obtained.
Embodiment 27
6.00g 6-caprolactones, 2.00g PEG-400, stannous octoate are weighed respectively(The 0.03wt% of total amount)As catalyst,
Add in vacuum reaction bottle, add a magnetic stir bar, vacuumize/inflated with nitrogen circulates 3 times, it is and close under vacuumized conditions
Vacuum reaction bottleneck is sealed, is put into 140 DEG C of oil bath pan and is reacted 24 h and obtain the polymer of line style.Weigh again 6gIPDI and
0.6g1,5- pentanediol, it is put into vacuum reaction bottle, is evacuated and hermetically sealed bottleneck, is put into 100 DEG C of oil bath pan and reacts 4h, obtain
To final product.
Embodiment 28
Weigh poly- (4- butyric esters) glycol of 10g(Molecular weight 4000), stannous octoate(The 0.03wt% of total amount)As urging
Agent, a magnetic stir bar is added, weighs 3gLDI and 0.6gBDO, is put into vacuum reaction bottle, vacuumize/inflated with nitrogen follows
Ring is evacuated and hermetically sealed bottleneck 3 times, is put into 70 DEG C of oil bath pan and reacts 4h, and vacuum reaction bottle is taken out and is cooled to room temperature,
Addition 0.6gL- LTIs are blocked in the environment of moisture is less than 10ppm, and 30min is stirred at room temperature and obtains
Final product.
Embodiment 29
Weigh 10gPLGA glycol, stannous octoate(The 0.03wt% of total amount)As catalyst, a magnetic stir bar is added,
3gL- lysine diisocyanates and 0.6g1, ammediol are weighed, is put into vacuum reaction bottle, vacuumizes/inflated with nitrogen circulation 3
It is secondary to be evacuated and hermetically sealed bottleneck, 70 DEG C of oil bath pan reaction 4h is put into, in the environment of moisture is less than 10ppm, will be reacted
Product is added in kneading machine, is added 0.6gDTT and is blocked, 30min is stirred at room temperature and obtains final product.
Embodiment 30
Glycolic (4g), L- lactic acid (12g) and BDO (1.1g) are weighed, 80 DEG C of high vacuum dry dehydrations in vacuum reaction bottle,
Stop reaction after 150 DEG C of reaction 48h, add HDI (2g) and stannous octoate (0.02wt% of total amount) in 70 DEG C of oil baths
6h is reacted in pot, obtains final product, adding 0.6gL- LTIs under vacuum environment is blocked, room temperature concussion
Or stirring 30min obtains final product.
Embodiment 31
Weigh glycolic (4g), DL- lactic acid (12g) and 1,6- hexylene glycol (1.8g), 80 DEG C of high vacuum in vacuum reaction bottle
Drying and dehydrating, 150 DEG C are reacted stopping reaction after 24h, add IPDI (2g) and stannous octoate (0.02wt% of total amount) exists
6h is reacted in 70 DEG C of oil bath pan, obtains final product, vacuum reaction bottle is taken out and is cooled to room temperature, adds 1.0gL- lysines
Triisocyanate is blocked, and is mediated stirring 30min repeatedly by kneader and is obtained final product.
Embodiment 32
Glycolic (8g), L- lactic acid (12g) and BDO (0.8g) are weighed, 80 DEG C of high vacuum dries take off in vacuum reaction bottle
Water, 150 DEG C are reacted stopping reaction after 24h, add LDI (2.8g) and stannous octoate (0.02wt% of total amount) at 70 DEG C
6h is reacted in oil bath pan, vacuum reaction bottle is taken out and is cooled to room temperature, 20ml tetrahydrofurans is added and dissolves material, add
1.6g DTT are blocked, and stirring 30min obtains final product.Obtain final product.
Embodiment 33
Weigh poly- (hexa-methylene carbonic ester) glycol of 10g, stannous octoate(The 0.03wt% of total amount)As catalyst, add
One magnetic stir bar, weighs 3gL- lysine diisocyanates and 0.6gBDO, is put into vacuum reaction bottle, vacuumizes/nitrogen charging
Gas is circulated 3 times and is evacuated and hermetically sealed bottleneck, is put into 70 DEG C of oil bath pan and reacts 4h, and vacuum reaction bottle is taken out and is cooled to room
Temperature, in the environment of moisture is less than 10ppm, adds 1.6gL- LTIs and blocked, is stirred at room temperature
30min obtains final product.
Biodegradable stent compound embodiment 1:Blood vessel covered stent
Its preparation process is as follows:
(1) degradable metal material is worked out, carved, etched or cut into the decorative pattern or lath-shaped of needs, stent diameter 1mm,
Long 2cm;
(2) will(1)The support polishing of middle preparation, 24h is soaked in mass percent is 30% hydrofluoric acid, with 75% after taking-up
Ethanol washing, dry;
(3) by polymer(The polyurethane that the present embodiment 2 obtains)It is dissolved in chloroform solvent, on tetrafluoroethene plate upper berth
The film thick into 0.2-0.3mm;
(4) will(3)The film roll of preparation exists(1)The metallic support metal material surface of middle preparation, is made overlay film frame;
(5) will(4)The composite of middle preparation passes through dip-coating or spraying hydrophilic coating(Such as chitosan, hyaluronic acid, glue
Aqueous solution etc. made of former, cellulose), dry up, polish, be polished to overlay film frame.
Biodegradable stent compound embodiment 2:Urethra overlay film frame
Using double sacculus urethra rack made of silica gel material, support pressure or be attached on cylinder balloon, after being put into urethra, to
Gas injection in sacculus, cylinder balloon strut support, are supported on urethra area.
Wherein peritonaeum urethra rack, its preparation process are as follows:
(1) degradable metal material is worked out, carved, etched or cut into the decorative pattern or lath-shaped of needs, stent diameter 3mm,
Long 2cm;
(2) the degradable medical polyurethane material and polymer B obtained the present embodiment 8: PLGA(Wherein LA:G/A ratio is
70:30, viscosity average molecular weigh is 80,000)By 1:2 mixed dissolutions are paved into 0.2- in dichloromethane solvent on tetrafluoroethene plate
Film thick 0.3mm;
(3) will(2)The film roll of preparation exists(1)The metallic support metal material surface of middle preparation, is made overlay film frame;
(4) will(3)The composite of middle preparation passes through dip-coating or spraying hydrophilic coating(Such as chitosan, hyaluronic acid, glue
Aqueous solution etc. made of former, cellulose), dry up, polish, be polished to overlay film frame.
Biodegradable stent compound embodiment 4:Ureter bracket
Its preparation process is as follows:
(1) by degradable metal material(The selection of alloying component ratio is by list 1 or content of magnesium 99%, Mn contents 1%
Magnesium-manganese alloy)External diameter 1mm, wall thickness 0.2mm, long 40cm pipe are pulled into, is engraved as the decorative pattern needed;
(2) the degradable medical polyurethane material and polymer B obtained embodiment 29: PLGA(Wherein LA:G/A ratio is 60:
40, viscosity average molecular weigh is 30,000)By 1:1 mixed dissolution is paved into 0.2-0.3mm in dichloromethane solvent on tetrafluoroethene plate
Thick film;
(3) will(2)The film roll of preparation exists(1)The metallic support metal material surface of middle preparation, is made overlay film frame;
(4) will(3)The composite of middle preparation passes through dip-coating or spraying hydrophilic coating(Such as chitosan, hyaluronic acid, glue
Aqueous solution etc. made of former, cellulose), dry up, polish, being polished to overlay film ureter bracket.
Biodegradable stent compound embodiment 5:With 3D printing technique prepare can gradient degradation ureter bracket
From the 3D printer with two feeding devices, magnesium alloy powder is added in a feeding device(Powder diameter is 30-
80um), high polymer material is added in another feeding device(Degradable medical polyurethane material and PLA are in proportion(1:1),
It is 30% solution to be configured to percentage concentration with chloroform), ureter bracket length(15-40cm, uniformly it is divided into 8 sections), magnesium alloy
Powder:High polymer material weight ratio from(1:1-1:8)It is divided into 8 part gradient printings, prints the support being sized with shape,
Heated-air drying volatilizes organic solvent and both obtained.
The support printed, the surface treatment such as dip-coating or spraying can be carried out according to product requirement.
Biodegradable stent compound embodiment 6:Intravascular stent is prepared with 3D printing technique
From the 3D printer with two feeding devices, magnesium alloy powder is added in a feeding device(Powder diameter is 30-
80um), high-temperature fusion prints the support of setting decorative pattern on demand, and Passivation Treatment is standby, is added in another feeding device high
Molecular material(Degradable medical polyurethane material and PLA are in proportion(1:3), being configured to percentage concentration with chloroform is
50% solution), coating film is printed, heated-air drying volatilizes organic solvent and both obtained.
Biodegradable stent compound embodiment 7:The implantation degradation experiment observation of urethra rack beasle dog
The double sacculus urethra racks that will be prepared in embodiment 1,2, use oxirane disinfection.6 body weight 12KG of selection or so ratio
Lattice dog, the urethra for being implanted into dog respectively are observed, every group 3, the swelling degree of postoperative routine observation urethra area, serology,
Histotomy is observed.Test result indicates that:Support in embodiment 1 starts to degrade after 2 weeks, and degraded in 6 weeks is complete;In embodiment 2
Support start to degrade within 4 weeks, 8 weeks are degradable, and urethra area tissue inflammation reaction is light, and histocompatbility is fine, have fine
Supporting role.
Described above is the preferred embodiment of the present invention, it is noted that for those skilled in the art
For, on the premise of principle of the present invention is not departed from, some improvements and modifications can also be made, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (10)
1. a kind of degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break, it is characterised in that is revived using two sulphur
Sugar alcohol, dihydric alcohol, amino acid, derivative and its salt of two amino of band and a molecule dihydric alcohol and two molecule amino acid are with two
One kind in the connected amino acids diamine of ester bond makees chain extender, wherein, amino acids diamine makees the structural formula of chain extender
It is as follows:
,
Wherein, P is dihydric alcohol, and X is 2-20 numeral, and m and n are the one kind for commonly using 20 kinds of amino acid.
2. degradation time according to claim 1 is controllable, the adjustable medical degradable polyurethane of elongation at break, its feature
It is, soft segment is the polymer of one or both of GA, LA, PDO, CL and PEG combination, and hard section is selected from diisocyanate,
Hard section is chosen in particular from:1,6- hexamethylene diisocyanate, isoflurane chalcone diisocyanate, lysine methyl ester diisocyanate,
Ethyl ester of lysine diisocyanate, cis-cyclohexane diisocyanate, trans-cyclohexane diisocyanate, Isosorbide-5-Nitrae-butane
Diisocyanate, butane diisocyanate, 1,2- ethane diisocyanate, 1,3- propane diisocyanate, 4,4 '-methylene
Base-bis- (cyclohexyl isocyanate), IPDI, 2,4,4- trimethyls 1, in 6- hexane diisocyanates
It is one or two kinds of;
The dihydric alcohol is chosen in particular from ethylene glycol, diethylene glycol (DEG), tetraethylene glycol, 1,3- propane diols, Isosorbide-5-Nitrae-butanediol, 1,5- penta 2
Alcohol, 1,6- hexylene glycols, 1,7- heptandiols, 1,8- ethohexadiols, 1,9- nonanediols, one kind in 1,10- decanediols or two
Kind.
3. a kind of degradation time is controllable, the preparation method of the adjustable medical degradable polyurethane of elongation at break, it is characterised in that
To control the elongation at break of polyurethane, prepared using two step method, specific preparation method is as follows:
(1)The synthesis of a variety of degradation times and the degradable polyurethane of physical property
Soft segment is selected from one or both of GA, LA, PDO, CL and PEG polymer, and hard section is in diisocyanate
One kind in one kind, preferably LDI, IPDI, HDI or 1,3- propane diisocyanate, chain extender selection amino acids diamines, is closed
It is as follows into scheme:
Soft segment compound or composition and catalyst are placed in vacuum reaction bottle by inventory, are put into 70-140 DEG C of oil bath pan
Middle reaction 4-24 h obtain the polymer of line style, then weigh the di-isocyanate reaction 0.5-12h of proper proportion, use appropriate solvent
Dissolve or be directly added into amino acids diamines chain extension and connect, be evacuated and hermetically sealed bottleneck, be put into 0-120 DEG C of oil bath pan and react 2-
12h, final product is obtained,
(2)Synthesis using amino acid as the degradable polyurethane of chain extender
Soft segment is selected from one or both of GA, LA, PDO, CL and PEG polymer, and hard section is in diisocyanate
One kind in one kind, preferably LDI, IPDI, HDI or 1,3- propane diisocyanate, chain extender are selected from the ammonia of two amino of band
Base acid, derivative and its salt, specifically include amino acid hydrochloride salt, such as lysine methyl ester dihydrochloride, the hydrochloric acid of ethyl ester of lysine two
Salt, cystine methyl esters dihydrochloride, cystine ethyl ester dihydrochloride, omithine methyl ester dihydrochloride, the hydrochloric acid of ornithine ethyl ester two
One kind in salt, synthetic schemes are as follows:
Soft segment compound or compound are combined, PDO, PEG or monomer CL, LA, GA is referred specifically to and catalyst is placed in by inventory
In vacuum reaction bottle, it is put into reaction 4-24 h in 70-140 DEG C of oil bath pan and obtains the polymer of line style, add diisocyanate
0.5-12h is reacted, the amino acids chain extender and triethylamine of proper proportion are dissolved or be directly added into appropriate solvent, is vacuumized simultaneously
Bottleneck is sealed, is put into 50-150 DEG C of oil bath pan and continues to react 2-24h, obtain final product;
(3)Soft segment is selected from the degradable polyurethane of PPDO, PDO and GA or PDO and CL copolymers:
Soft segment is selected from PPDO, PDO and GA or one or both of CL and PDO and combined, hard section in isocyanates one
Kind, preferably one kind in LDI, IPDI, HDI or 1,3- propane diisocyanate, chain extender select 1, ammediol, synthesis side
Case is as follows:
Anhydrous PPDO, PDO and GA or CL and PDO and catalyst by proportion are placed in vacuum reaction bottle, are put into 120-160 DEG C
Oil bath pan in reaction 4-24 h obtain the polymer of line style, add the 1B di-isocyanate reaction 0.5- of proper proportion
12h, dissolved with appropriate solvent or be directly added into 1, ammediol, be put into vacuum reaction bottle, be evacuated and hermetically sealed bottleneck, be put into
2-24h is reacted in 50-150 DEG C of oil bath pan, obtains final product;
The one kind of the catalyst in stannous octoate, organic zinc or organic bismuth salt, dosage are the 0.001- of total amount of feeding
10wt%;The organic solvent is selected from high boiling solvent, specifically includes fatty alcohol, DMSO, DMF, 1,4- dioxane, positive fourth
One kind in alcohol, isobutanol, dimethylbenzene and toluene;
Obtained degradable polyurethane elongation at break is different according to soft and hard segments component, adjustable in the range of 100%-700%.
4. degradation time according to claim 3 is controllable, the preparation of the adjustable medical degradable polyurethane of elongation at break
Method, it is characterised in that the chain extender is selected from LTI or DTT, described with the webbed cross-linked structure of shape
The elongation at break of urethane composition is higher than 300MPa, and elongation at break is in the range of 30%~700%, and reaction is selected from as follows
One of mode:
(1)Degradable polyurethane prepared by two step method in claim 3, adds two sulphur threoses during second step chain extension
Alcohol or LTI, reacted 20 minutes in double screw extruder of the moisture less than 10ppm, stirring polymerization is squeezed
Go out, obtain the urethane composition with high elongation at tear;
(2)Degradable polyurethane prepared by two step method in claim 3 is small in moisture during second step chain extension
Poured into the environment of 10ppm in kneading machine or kneader, be directly added into dithiothreitol (DTT) or LTI fills
Divide stirring, normal-temperature reaction half an hour obtains the urethane composition with high elongation at tear;
(3)Degradable polyurethane prepared by two step method in claim 3, is added anhydrous organic during second step chain extension
Solvent is configured to viscous solution, and DTT or LTI are directly added into the environment of moisture is less than 10ppm,
Reaction system stirs or concussion mixing, and vacuum drains organic solvent and obtains having high elongation at tear after normal-temperature reaction half an hour
Urethane composition.
5. a kind of degradation time any one of claim 1 ~ 4 is controllable, the adjustable medical degradable of elongation at break gathers
The application of urethane, it is characterised in that for preparing medical embedded material, the medical embedded material can be used alone, can be compound
Compound use is made in other high polymer material blendings, can be used for implantation equipment, implantable artificial organs, the artificial device of contact
Official, support, interposing catheter, artificial skin, tissue engineering bracket and organ servicing unit, when as medical embedded material,
Further purification is needed to remove toxic monomers or organic solvent.
6. degradation time according to claim 5 is controllable, the application of the adjustable medical degradable polyurethane of elongation at break,
Characterized in that, the medical embedded material includes contrast agent, it is extremely similar that the contrast agent is selected from conventional radiocontrast medium
Thing, in addition to zirconium, barium, Dian, Manganese, iron, lanthanum, cerium, praseodymium, etc. combination or form complexed ionic species.
7. a kind of degradation time any one of claim 1 ~ 4 is controllable, the adjustable medical degradable of elongation at break gathers
The application of urethane, it is characterised in that the medical degradable polyurethane can be compound with degradation material, is made degradable compound
Material is implanted into, the degradation material includes degradable high polymer material and degradable metal material, wherein, it is described medical to drop
Polyurethane is solved with the weight ratio of degradable metal material in 0.1-99%:In the range of 1%-99.9%, the degradable metal material bag
Include iron of the purity more than 99.0%, purity is more than 99.0% magnesium, percentage by weight 1:0.01-10 Mg-Fe alloy, weight percent
Than for 1:0.01-1 Mg-Zn based alloy, percentage by weight 1:0.01-1 magnesium calcium alloy, percentage by weight 1:0.01-
One or both of 0.1 Magnesium-aluminum alloys combine.
8. a kind of degradation time any one of claim 1 ~ 4 is controllable, the adjustable medical degradable of elongation at break gathers
The application of urethane, it is characterised in that the medical degradable polyurethane is used to prepare biodegradable stent compound, including following step
Suddenly:
(1)Degradable metal material is worked out, carved, etched or cut into the decorative pattern or lath-shaped metallic support of needs, preferably
Decorative pattern a diameter of 0.01 to 3mm;
(2)Medical degradable polyurethane, polyurethane and the combination of other high polymer materials it will be dissolved in as described in claim 1-4
In solvent, coating material is made;
(3)By step(2)The coating material of preparation dip-coating, even application or is made film and is attached to step repeatedly(1)The gold of preparation
Belong to rack surface, the compound rest with overlay film is made, the thickness of the overlay film is in the range of 0.001-1mm, preferably 0.01-
0.5mm;
(4)By step(3)The compound rest with overlay film of middle preparation is by dip-coating or spraying hydrophilic coating, and polishing grinding is into can
Degraded scaffold complex.
9. a kind of degradation time any one of claim 1 ~ 4 is controllable, the adjustable medical degradable of elongation at break gathers
The application of urethane, it is characterised in that the medical degradable polyurethane is used to prepare biodegradable stent compound, described degradable
The preparation method of scaffold complex is one of following method:
(1)Magnesium alloy powder is well mixed with the solution of the urethane composition as any one of claim 1-4, led to
Cross 3D printer and print the support for needing diameter and wall thickness, the dry organic solvent of heated-air drying volatilization, obtain biodegradable stent and answer
Compound;
(2)3D printer is set into two feeding devices, adds magnesium alloy powder in a feeding device, another feeding device
The solution of middle urethane composition of the addition as any one of claim 1-4, two kinds of materials during charging by than
The support being sized with shape is printed after example mixing, the dry organic solvent of heated-air drying volatilization, it is compound to obtain biodegradable stent
Thing;
(3)3D printer sets two feeding devices, magnesium alloy powder is added in a feeding device, in another feeding device
Be proportionally added into urethane composition and PLA as any one of claim 1-4, be mixed be dissolved in it is organic
In solvent, it is 20-90% to be configured to percentage concentration with organic solvent, and two kinds of materials print after being mixed in proportion during charging
Go out the support being sized with shape, the dry organic solvent of heated-air drying volatilization, obtain biodegradable stent compound;
(4)3D printer sets two feeding devices, adds magnesium alloy powder in a feeding device, high-temperature fusion is beaten on demand
Support is printed off, Passivation Treatment is standby;It is proportionally added into another feeding device poly- as any one of claim 1-4
Urethane composition and PLA, are then mixed and are dissolved in organic solvent, and being configured to percentage concentration with organic solvent is
20-90%, coating film is printed on support, the dry organic solvent of heated-air drying volatilization, obtains biodegradable stent compound.
10. the application of biodegradable stent compound prepared by a kind of any one of claim 8 or 9, it is characterised in that it is described
Structure, composition and the shape of biodegradable stent compound be applied to blood vessel, vein, oesophagus, biliary tract, trachea-bronchial epithelial cell, small intestine,
Large intestine, urethra, ureter or other fragments close to tubular body passage.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710971002.9A CN107778446A (en) | 2017-10-18 | 2017-10-18 | Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break |
PCT/CN2018/106407 WO2019076178A1 (en) | 2017-10-18 | 2018-09-19 | Degradation time controllable and breaking elongation adjustable medical degradable polyurethane |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710971002.9A CN107778446A (en) | 2017-10-18 | 2017-10-18 | Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107778446A true CN107778446A (en) | 2018-03-09 |
Family
ID=61434605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710971002.9A Pending CN107778446A (en) | 2017-10-18 | 2017-10-18 | Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107778446A (en) |
WO (1) | WO2019076178A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107828044A (en) * | 2017-11-15 | 2018-03-23 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | A kind of degradable double J pipe |
CN108421086A (en) * | 2018-04-19 | 2018-08-21 | 济南羽时信息科技有限公司 | A kind of nanometer hydroxyapatite modified polyurethane urea bone renovating material and preparation method thereof |
CN108515175A (en) * | 2018-05-08 | 2018-09-11 | 东南大学 | A kind of magnesium alloy slurry and its Method of printing |
CN108530607A (en) * | 2018-04-19 | 2018-09-14 | 济南羽时信息科技有限公司 | A kind of chitosan oligosaccharide modified polyurethane urea bone renovating material and preparation method thereof |
CN109395174A (en) * | 2018-12-28 | 2019-03-01 | 上海纳米技术及应用国家工程研究中心有限公司 | The preparation method and products thereof of the anti-degradable trachea bracket of scar |
CN109503797A (en) * | 2018-10-28 | 2019-03-22 | 凯斯蒂南京医疗器械有限公司 | A kind of medical degradable polyurethane and application thereof with antibacterial activity |
WO2019076178A1 (en) * | 2017-10-18 | 2019-04-25 | 凯斯蒂南京医疗器械有限公司 | Degradation time controllable and breaking elongation adjustable medical degradable polyurethane |
CN110680960A (en) * | 2018-07-04 | 2020-01-14 | 苏州纳晶医药技术有限公司 | A controllable gradient degradable helical covered stent, its preparation method and use |
CN111379045A (en) * | 2020-05-15 | 2020-07-07 | 中原工学院 | Elasticity-controllable spandex and preparation method thereof |
CN112143210A (en) * | 2020-08-28 | 2020-12-29 | 东莞市吉鑫高分子科技有限公司 | Amphiphilic biodegradable thermoplastic polyurethane elastomer and preparation method thereof |
CN112210060A (en) * | 2020-07-21 | 2021-01-12 | 北京科技大学 | Self-repairing green high-toughness polyurethane elastomer and preparation method thereof |
CN112979912A (en) * | 2021-02-25 | 2021-06-18 | 苏州大学 | Ultra-high-toughness polylactic acid-based polyurethane urea and preparation method thereof |
US20210187157A1 (en) * | 2019-12-19 | 2021-06-24 | Industrial Technology Research Institute | Biodegradable iron-based alloy composition, medical implant applying the same, and manufacturing method thereof |
CN114539623A (en) * | 2022-02-24 | 2022-05-27 | 华北科技学院(中国煤矿安全技术培训中心) | Application of chitosan-based flame retardant in polyurethane |
CN114699566A (en) * | 2022-04-08 | 2022-07-05 | 刘家起 | Preparation method of absorbable ligation clip |
CN114805460A (en) * | 2022-05-31 | 2022-07-29 | 温州大学 | DNA-cholesterol functionalized dendrimer hybrid and synthesis method and application thereof |
CN116920180A (en) * | 2023-09-14 | 2023-10-24 | 乐普(北京)医疗器械股份有限公司 | A kind of degradable metal material and its preparation method and application |
CN118649277A (en) * | 2024-08-22 | 2024-09-17 | 四川大学华西医院 | A radioactive iodine-loaded manganese-based metal organic framework degradable embolic microsphere and its preparation method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2219545A1 (en) * | 1997-10-28 | 1999-04-28 | Kimberly Woodhouse | Biodegradable materials for wound dressing |
CN101636187A (en) * | 2007-01-30 | 2010-01-27 | 汉莫堤克股份有限公司 | Biodegradable vascular support |
CN101654508A (en) * | 2009-09-25 | 2010-02-24 | 北京理工大学 | Degradable and nontoxic medical polyurethane material and preparation method thereof |
CN102225931A (en) * | 2011-01-30 | 2011-10-26 | 上海师范大学 | Divalent cis-neonicotinoid compound containing amino acid ester and its preparation method and application |
CN105169496A (en) * | 2015-09-30 | 2015-12-23 | 苏州纳晶医药技术有限公司 | Biodegradable stent composite |
CN107638587A (en) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | With tissue inducing function without scar regeneration medical dressing and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105457092A (en) * | 2015-10-12 | 2016-04-06 | 圆容生物医药无锡有限公司 | Polyurethane (PU) composition with adjustable elasticity modulus and application of PU composition in medical implant materials |
CN107778446A (en) * | 2017-10-18 | 2018-03-09 | 圆容生物医药无锡有限公司 | Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break |
-
2017
- 2017-10-18 CN CN201710971002.9A patent/CN107778446A/en active Pending
-
2018
- 2018-09-19 WO PCT/CN2018/106407 patent/WO2019076178A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2219545A1 (en) * | 1997-10-28 | 1999-04-28 | Kimberly Woodhouse | Biodegradable materials for wound dressing |
CN101636187A (en) * | 2007-01-30 | 2010-01-27 | 汉莫堤克股份有限公司 | Biodegradable vascular support |
CN101654508A (en) * | 2009-09-25 | 2010-02-24 | 北京理工大学 | Degradable and nontoxic medical polyurethane material and preparation method thereof |
CN102225931A (en) * | 2011-01-30 | 2011-10-26 | 上海师范大学 | Divalent cis-neonicotinoid compound containing amino acid ester and its preparation method and application |
CN105169496A (en) * | 2015-09-30 | 2015-12-23 | 苏州纳晶医药技术有限公司 | Biodegradable stent composite |
CN107638587A (en) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | With tissue inducing function without scar regeneration medical dressing and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
HAO-YANG MI ETC.: "Post-crosslinkable biodegradable thermoplastic polyurethanes: Synthesis, and thermal, mechanical, and degradation properties", 《MATERIALS & DESIGN》 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019076178A1 (en) * | 2017-10-18 | 2019-04-25 | 凯斯蒂南京医疗器械有限公司 | Degradation time controllable and breaking elongation adjustable medical degradable polyurethane |
CN107828044A (en) * | 2017-11-15 | 2018-03-23 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | A kind of degradable double J pipe |
CN108421086B (en) * | 2018-04-19 | 2020-11-03 | 济南羽时信息科技有限公司 | Nano-hydroxyapatite modified polyurethane urea bone repair material and preparation method thereof |
CN108421086A (en) * | 2018-04-19 | 2018-08-21 | 济南羽时信息科技有限公司 | A kind of nanometer hydroxyapatite modified polyurethane urea bone renovating material and preparation method thereof |
CN108530607A (en) * | 2018-04-19 | 2018-09-14 | 济南羽时信息科技有限公司 | A kind of chitosan oligosaccharide modified polyurethane urea bone renovating material and preparation method thereof |
CN108530607B (en) * | 2018-04-19 | 2020-07-28 | 济南羽时信息科技有限公司 | Chitosan oligosaccharide modified polyurethane urea bone repair material and preparation method thereof |
CN108515175A (en) * | 2018-05-08 | 2018-09-11 | 东南大学 | A kind of magnesium alloy slurry and its Method of printing |
CN110680960A (en) * | 2018-07-04 | 2020-01-14 | 苏州纳晶医药技术有限公司 | A controllable gradient degradable helical covered stent, its preparation method and use |
CN109503797A (en) * | 2018-10-28 | 2019-03-22 | 凯斯蒂南京医疗器械有限公司 | A kind of medical degradable polyurethane and application thereof with antibacterial activity |
CN109395174A (en) * | 2018-12-28 | 2019-03-01 | 上海纳米技术及应用国家工程研究中心有限公司 | The preparation method and products thereof of the anti-degradable trachea bracket of scar |
US20210187157A1 (en) * | 2019-12-19 | 2021-06-24 | Industrial Technology Research Institute | Biodegradable iron-based alloy composition, medical implant applying the same, and manufacturing method thereof |
CN111379045B (en) * | 2020-05-15 | 2022-07-26 | 中原工学院 | A kind of elastic controllable spandex and preparation method thereof |
CN111379045A (en) * | 2020-05-15 | 2020-07-07 | 中原工学院 | Elasticity-controllable spandex and preparation method thereof |
CN112210060A (en) * | 2020-07-21 | 2021-01-12 | 北京科技大学 | Self-repairing green high-toughness polyurethane elastomer and preparation method thereof |
CN112210060B (en) * | 2020-07-21 | 2022-04-22 | 北京科技大学 | A kind of self-repairable, green high-toughness polyurethane elastomer and preparation method |
CN112143210A (en) * | 2020-08-28 | 2020-12-29 | 东莞市吉鑫高分子科技有限公司 | Amphiphilic biodegradable thermoplastic polyurethane elastomer and preparation method thereof |
CN112143210B (en) * | 2020-08-28 | 2022-05-27 | 东莞市吉鑫高分子科技有限公司 | A kind of amphiphilic biodegradable thermoplastic polyurethane elastomer and preparation method thereof |
CN112979912B (en) * | 2021-02-25 | 2022-07-12 | 苏州大学 | Ultra-high-toughness polylactic acid-based polyurethane urea and preparation method thereof |
CN112979912A (en) * | 2021-02-25 | 2021-06-18 | 苏州大学 | Ultra-high-toughness polylactic acid-based polyurethane urea and preparation method thereof |
WO2022178915A1 (en) * | 2021-02-25 | 2022-09-01 | 苏州大学 | Polylactic acid-based polyurethane-urea with super-strong toughness, and preparation method therefor |
CN114539623A (en) * | 2022-02-24 | 2022-05-27 | 华北科技学院(中国煤矿安全技术培训中心) | Application of chitosan-based flame retardant in polyurethane |
CN114699566A (en) * | 2022-04-08 | 2022-07-05 | 刘家起 | Preparation method of absorbable ligation clip |
CN114699566B (en) * | 2022-04-08 | 2022-12-20 | 海泽临床成果转化医学研究院(无锡)有限公司 | Preparation method of absorbable ligation clip |
CN114805460A (en) * | 2022-05-31 | 2022-07-29 | 温州大学 | DNA-cholesterol functionalized dendrimer hybrid and synthesis method and application thereof |
CN114805460B (en) * | 2022-05-31 | 2023-10-24 | 温州大学 | DNA-cholesterol functionalized dendrimer hybrid, and synthetic method and application thereof |
CN116920180A (en) * | 2023-09-14 | 2023-10-24 | 乐普(北京)医疗器械股份有限公司 | A kind of degradable metal material and its preparation method and application |
CN116920180B (en) * | 2023-09-14 | 2023-12-15 | 乐普(北京)医疗器械股份有限公司 | Degradable metal material and preparation method and application thereof |
CN118649277A (en) * | 2024-08-22 | 2024-09-17 | 四川大学华西医院 | A radioactive iodine-loaded manganese-based metal organic framework degradable embolic microsphere and its preparation method |
Also Published As
Publication number | Publication date |
---|---|
WO2019076178A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107778446A (en) | Degradation time is controllable, the adjustable medical degradable polyurethane of elongation at break | |
CN109503797A (en) | A kind of medical degradable polyurethane and application thereof with antibacterial activity | |
WO2017054433A1 (en) | Elastic modulus adjustable polyurethane composition, scaffold composite and preparation method thereof | |
CN105169496A (en) | Biodegradable stent composite | |
ES2451653T3 (en) | Implantable medical device with surface erosion polyester drug supply coating | |
JP5153340B2 (en) | Drug release control composition and drug release medical device | |
JP5743136B2 (en) | Implantable medical devices made from polyurethane with biodegradable hard and soft blocks and blends thereof | |
JP4617258B2 (en) | Method for producing biocompatible stent for use in the body of a subject | |
JP5581202B2 (en) | Dihydroxybenzoate polymer and use thereof | |
US20210128795A1 (en) | Spiral coated stent with controllable gradient degradation, preparation method thereof and application thereof | |
JP2009505726A (en) | Medical devices and coatings with improved functionality by including biodegradable polymers | |
JP6518198B2 (en) | Compounds and compositions for drug release | |
CN105457092A (en) | Polyurethane (PU) composition with adjustable elasticity modulus and application of PU composition in medical implant materials | |
WO2011143237A1 (en) | Glycerol ester active agent delivery systems and methods | |
CN109893682A (en) | A kind of degradable metal ureter bracket and preparation method with composite construction | |
Sanchez-Rexach et al. | Recent developments in drug eluting devices with tailored interfacial properties | |
CN103110985A (en) | Biodegradable bracket with multiple drugs | |
WO2020087896A1 (en) | Medical degradable polyurethane having antibacterial activity and application thereof | |
CN101641059A (en) | Intracoronary stent with asymmetric drug releasing controlled coating | |
CN104168927B (en) | Coating composition and medical apparatus and instruments | |
CN115558078A (en) | Degradable polyurethane and application thereof | |
CN205569125U (en) | Degradable urethra support composition that two sacculus catheters supported | |
CN106267382A (en) | A kind of degradable bracket for eluting medicament and preparation method thereof | |
Hassan et al. | Engineered Biomaterials: Progress and Prospects | |
US20130344126A1 (en) | Bioerodable poly(etheresteramides) and medical article uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180309 |